10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

Commission File Number 1-6926

C. R. BARD, INC.

(Exact name of registrant as specified in its charter)

New Jersey	730 Central Avenue Murray Hill, New Jersey 07974	22-1454160
(State of incorporation)	(Address of principal executive offices)	(I.R.S. Employer Identification No.)

Registrant’s telephone number, including area code: (908) 277-8000

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	¨
Non-accelerated filer	¨  (Do not check if smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class	Outstanding at September 30, 2012
Common Stock - $0.25 par value	82,311,961

C. R. BARD, INC. AND SUBSIDIARIES

INDEX

		Page
PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited)
	Condensed Consolidated Statements of Income for the Quarter and Nine Months Ended September 30, 2012 and 2011		3
	Condensed Consolidated Statements of Comprehensive Income for the Quarter and Nine Months Ended September 30, 2012 and 2011		4
	Condensed Consolidated Balance Sheets – September 30, 2012 and December 31, 2011		5
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2012 and 2011		6
	Notes to Condensed Consolidated Financial Statements		7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		27
Item 4.	Controls and Procedures		27
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings		28
Item 1A.	Risk Factors		30
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		31
Item 5.	Other Information		31
Item 6.	Exhibits		31
Signatures			32

2

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(dollars in thousands except per share amounts, unaudited)

	Quarter Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Net sales	$	722,900	$	719,200	$	2,195,500	$	2,144,500
Costs and expenses:
Cost of goods sold		272,600		274,900		837,700		815,200
Marketing, selling and administrative expense		196,600		189,300		604,300		580,400
Research and development expense		52,200		46,900		150,500		141,800
Interest expense		9,700		9,000		28,900		27,100
Other (income) expense, net		13,600		17,000		19,000		211,200
Total costs and expenses		544,700		537,100		1,640,400		1,775,700
Income from operations before income taxes		178,200		182,100		555,100		368,800
Income tax provision		48,900		52,000		153,200		154,600
Net income	$	129,300	$	130,100	$	401,900	$	214,200
Basic earnings per share available to common shareholders	$	1.52	$	1.48	$	4.70	$	2.44
Diluted earnings per share available to common shareholders	$	1.50	$	1.46	$	4.64	$	2.40

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(dollars in thousands, unaudited)

	Quarter Ended September 30,					Nine Months Ended September 30,
	2012		2011			2012			2011
Net income	$	129,300	$	130,100		$	401,900		$	214,200
Other comprehensive income (loss), net of tax
Change in derivative instruments designated as cash flow hedges		100		(4,100	)		2,100			(4,100	)
Foreign currency translation adjustments		14,900		(9,400	)		(24,300	)		41,900
Benefit plan adjustments		1,800		1,300			5,200			3,900
Available-for-sale securities		—		2,100			—			—
Other comprehensive income (loss)		16,800		(10,100	)		(17,000	)		41,700
Comprehensive income	$	146,100	$	120,000		$	384,900		$	255,900

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(dollars in thousands except share and per share amounts, unaudited)

	September 30, 2012			December 31, 2011
ASSETS
Current assets
Cash and cash equivalents	$	809,100		$	596,400
Restricted cash		27,500			147,100
Accounts receivable, less allowances of $11,700 and $10,000, respectively		475,000			488,900
Inventories		335,900			319,200
Short-term deferred tax assets		58,200			61,200
Other current assets		79,700			73,100
Total current assets		1,785,400			1,685,900
Property, plant and equipment, at cost		641,800			627,500
Less accumulated depreciation and amortization		287,500			272,100
Net property, plant and equipment		354,300			355,400
Goodwill		905,800			916,700
Core technologies, net		444,500			498,700
Other intangible assets, net		343,800			352,600
Deferred tax assets		8,700			19,700
Other assets		90,000			102,100
Total assets	$	3,932,500		$	3,931,100
LIABILITIES AND SHAREHOLDERS’ INVESTMENT
Current liabilities
Short-term borrowings	$	381,500		$	304,500
Accounts payable		64,800			86,400
Accrued expenses		224,100			380,400
Accrued compensation and benefits		104,700			124,400
Income taxes payable		9,600			8,400
Total current liabilities		784,700			904,100
Long-term debt		911,400			908,700
Other long-term liabilities		322,000			319,600
Deferred income taxes		16,600			16,500
Commitments and contingencies		—			—
Shareholders’ investment:
Preferred stock, $1 par value, authorized 5,000,000 shares; none issued		—			—
Common stock, $0.25 par value, authorized 600,000,000 shares; issued and outstanding 82,311,961 shares at September 30, 2012 and 84,543,338 shares at December 31, 2011		20,600			21,200
Capital in excess of par value		1,480,700			1,349,800
Retained earnings		480,100			477,800
Accumulated other comprehensive loss		(83,600	)		(66,600	)
Total shareholders’ investment		1,897,800			1,782,200
Total liabilities and shareholders’ investment	$	3,932,500		$	3,931,100

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

C. R. BARD, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(dollars in thousands, unaudited)

	Nine Months Ended September 30,
	2012			2011
Cash flows from operating activities:
Net income	$	401,900		$	214,200
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		101,400			84,400
Asset impairments		22,200			—
Restructuring, net of payments		(1,600	)		7,800
Impairment charge for foreign government bonds		—			7,000
Legal settlements and commitments, net of payments		—			184,800
Acquired in-process research and development		2,000			3,500
Deferred income taxes		12,600			(12,200	)
Share-based compensation		39,000			36,700
Inventory reserves and provision for doubtful accounts		15,000			10,900
Other items		(5,800	)		(2,100	)
Changes in assets and liabilities:
Accounts receivable		31,600			(14,300	)
Inventories		(34,000	)		(19,800	)
Current liabilities		(153,900	)		2,000
Taxes		(2,500	)		36,600
Other, net		(700	)		9,900
Net cash provided by operating activities		427,200			549,400
Cash flows from investing activities:
Capital expenditures		(55,500	)		(49,900	)
Change in restricted cash		119,600			(200,300	)
Payments made for intangibles		(14,100	)		(16,600	)
Proceeds from sale of financial instruments		10,000			—
Net cash provided by (used in) investing activities		60,000			(266,800	)
Cash flows from financing activities:
Change in short-term borrowings, net		77,000			(80,500	)
Proceeds from exercises under share-based compensation plans, net		70,200			96,100
Excess tax benefit relating to share-based compensation plans		10,300			23,800
Purchases of common stock		(372,500	)		(155,100	)
Dividends paid		(49,900	)		(48,200	)
Other		(4,900	)		(2,200	)
Net cash used in financing activities		(269,800	)		(166,100	)
Effect of exchange rate changes on cash and cash equivalents		(4,700	)		9,100
Increase in cash and cash equivalents during the period		212,700			125,600
Balance at January 1		596,400			641,400
Balance at September 30	$	809,100		$	767,000
Supplemental cash flow information
Cash paid for:
Interest	$	31,600		$	20,100
Income taxes		132,800			106,400
Non-cash transactions:
Receipt of foreign government bonds		—			16,800
Purchase of common stock not settled		9,100			19,100

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of C. R. Bard, Inc. and its subsidiaries (the “company” or “Bard”) should be read in conjunction with the audited consolidated financial statements and notes thereto included in Bard’s 2011 Annual Report on Form 10-K. These financial statements have been prepared on a basis that is substantially consistent with the accounting principles applied in the financial statements in Bard’s 2011 Annual Report on Form 10-K. The preparation of these financial statements requires the company to make estimates and judgments that affect reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities at the date of the financial statements. These financial statements include all normal and recurring adjustments necessary for a fair presentation. The accounts of most foreign subsidiaries are consolidated as of and for the quarter and nine months ended August 31, 2012 and August 31, 2011 and as of November 30, 2011. No events occurred related to these foreign subsidiaries during the months of September 2012, September 2011 or December 2011 that materially affected the financial position or results of operations of the company. The results for the interim periods presented are not necessarily indicative of the results expected for the year.

2. Acquisition

On October 19, 2012, the company acquired Neomend, Inc. (“Neomend”), a privately-held company engaged in the development and commercialization of innovative surgical sealants. The purchase consideration consists of an up front cash payment of $140 million and contingent consideration of up to $25 million, based on the achievement of sales-based milestone payments through 2016. Neomend’s products expand Bard’s existing surgical specialties product portfolio to include the only product approved by the U.S. Food and Drug Administration for the treatment of intraoperative air leaks in connection with thoracic surgery. Neomend’s proprietary technology and pipeline provides the opportunity for future clinical indications across a variety of surgical specialty applications. The company has not yet completed the initial purchase accounting due to the timing of this acquisition.

3. Asset Impairments and Restructuring

During the third quarter of 2012, the company recorded an asset impairment charge of $13.2 million ($8.0 million after tax). This charge relates to the write-down of certain core technologies associated with a non-strategic product in the company’s vascular product group. During the second quarter of 2012, the company recorded asset impairment charges of $9.0 million ($5.8 million after tax). The charges in the second quarter reflect impairments of assets not related to operations. These asset impairment charges were recorded to other (income) expense, net.

During the second half of 2011, the company initiated certain restructuring actions in order to improve its overall cost structure and enhance operational effectiveness. These actions included the realignment of certain sales functions in the United States. At September 30, 2012, the remaining liability related to these restructuring actions was $1.0 million, which reflects cash payments made in 2012 of $4.8 million and a reversal of $1.6 million of restructuring costs. The company expects activities under these restructuring actions to be substantially complete by the end of 2012.

4. Earnings per Common Share

Earnings per share (“EPS”) is computed under the two-class method using the following common share information:

	Quarter Ended September  30,				Nine Months Ended September 30,
	2012		2011		2012		2011
(dollars and shares in millions)
EPS Numerator:
Net income	$	129.3	$	130.1	$	401.9	$	214.2
Less: Income allocated to participating securities		2.4		2.3		7.7		4.0
Net income available to common shareholders	$	126.9	$	127.8	$	394.2	$	210.2
EPS Denominator:
Weighted average common shares outstanding		83.4		86.6		83.8		86.0
Dilutive common share equivalents from share-based compensation plans		1.2		1.2		1.1		1.7
Weighted average common and common equivalent shares outstanding, assuming dilution		84.6		87.8		84.9		87.7

7

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

5. Income Taxes

The effective tax rate for the quarter ended September 30, 2012 was approximately 27% compared to approximately 29% for the same period in 2011. The effective tax rate for the nine months ended September 30, 2012 was approximately 28% compared to approximately 42% for the same period in 2011. The higher effective tax rate for the prior nine month period reflected the discrete tax effect of a charge for legal settlements, primarily related to Hernia Product Claims (see Note 8 of the notes to condensed consolidated financial statements), which were incurred in a low tax jurisdiction. At September 30, 2012, the total amount of liability for unrecognized tax benefits related to federal, state and foreign taxes was $41.0 million (of which $34.7 million would impact the effective tax rate, if recognized) plus $5.7 million of accrued interest. At December 31, 2011, the liability for unrecognized tax benefits was $45.0 million plus $5.0 million of accrued interest. Depending upon the result of open tax examinations and/or the expiration of applicable statutes of limitation, the company believes it is reasonably possible that the total amount of unrecognized tax benefits may decrease by up to $2.5 million within the next 12 months.

6. Financial Instruments

Foreign Exchange Derivative Instruments

The company enters into readily marketable forward and option contracts with financial institutions to help reduce its exposure to foreign currency exchange rate fluctuations. These contracts limit volatility because gains and losses associated with foreign currency exchange rate movements are generally offset by movements in the underlying hedged item. The notional value of the company’s forward currency and option currency contracts was $165.5 million and $205.2 million at September 30, 2012 and December 31, 2011, respectively. For further discussion regarding the company’s use of derivative instruments, see Note 1 of the consolidated financial statements in Bard’s 2011 Annual Report on Form 10-K.

Interest Rate Derivative Instrument

The company’s outstanding interest rate swap contract effectively converts its 2.875% fixed-rate notes due 2016 to a floating-rate instrument. The notional value of the company’s interest rate swap contract is $250.0 million.

The location and fair value of derivative instruments segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:

	Balance Sheet Location	Fair Value of Derivatives
Derivatives Designated as Hedging Instruments		September 30, 2012		December 31, 2011
(dollars in millions)
Forward currency contracts	Other current assets	$	1.3	$	1.5
Option currency contracts	Other current assets		2.7		4.3
Forward currency contracts	Other assets		0.3		—
Option currency contracts	Other assets		0.6		—
Interest rate swap contract	Other assets		14.6		12.1
		$	19.5	$	17.9
Forward currency contracts	Accrued expenses	$	0.8	$	6.4
Forward currency contracts	Other long-term liabilities		0.1		—
		$	0.9	$	6.4
Derivatives Not Designated as Hedging Instruments
(dollars in millions)
Forward currency contracts	Other current assets	$	—	$	3.8
		$	—	$	3.8

8

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders’ investment are as follows:

	Gain/(Loss) Recognized  in Other Comprehensive Income						Location of Gain/(Loss) Reclassified from Accumulated Other Comp. Loss to Income	Gain/(Loss)  Reclassified from Accumulated Other Comp. Loss into Income
	Quarter Ended September 30,							Quarter Ended September  30,
	2012			2011				2012			2011
(dollars in millions)
Forward currency contracts	$	1.2		$	(4.3	)	Costs of goods sold	$	(0.3	)	$	(0.1	)
Option currency contracts		(1.1	)		0.2		Costs of goods sold		0.5			—
	$	0.1		$	(4.1	)		$	0.2		$	(0.1	)
	Gain/(Loss) Recognized in  Other Comprehensive Income						Location of Gain/(Loss) Reclassified from Accumulated Other Comp. Loss to Income	Gain/(Loss) Reclassified from Accumulated Other Comp. Loss into Income
	Nine Months Ended September 30,							Nine Months Ended September 30,
	2012			2011				2012			2011
(dollars in millions)
Forward currency contracts	$	3.3		$	(4.2	)	Costs of goods sold	$	(0.2	)	$	0.8
Option currency contracts		(1.2	)		0.1		Costs of goods sold		1.1			—
	$	2.1		$	(4.1	)		$	0.9	(A)	$	0.8	(A)

^(A)  The tax effect of the amount reclassified from accumulated other comprehensive loss to income was $0.2 million and $0.7 million at September 30, 2012 and 2011, respectively.

The location and amounts of gains and losses on the derivative instrument designated as a fair value hedge are as follows:

	Income  Statement Location	Gain Recognized on Swap								Loss Recognized on Long-Term Debt
		Quarter Ended September  30,				Nine Months  Ended September 30,				Quarter Ended September  30,						Nine Months  Ended September 30,
		2012		2011		2012		2011		2012			2011			2012			2011
(dollars in millions)
Interest rate swap contract	Interest expense	$	1.0	$	7.7	$	2.5	$	11.7	$	(1.0	)	$	(7.7	)	$	(2.5	)	$	(11.7	)

The location and amounts of gains and losses on derivative instruments not designated as hedging instruments are as follows:

	Income  Statement Location	Gain/(Loss) Recognized in Earnings
		Quarter Ended September  30,					Nine Months  Ended September 30,
		2012		2011			2012		2011
(dollars in millions)
Forward currency contracts(A)	Other (income) expense, net	$	—	$	(5.1	)	$	3.0	$	(0.5	)

^(A) These derivative contracts mitigate changes in the value of remeasured foreign currency denominated intercompany loans attributable to changes in foreign currency exchange rates.

9

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Financial Instruments Measured at Fair Value on a Recurring Basis

Fair value is defined as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy range from Level 1 having observable inputs to Level 3 having unobservable inputs.

The following table summarizes certain financial instrument assets and (liabilities) measured at fair value on a recurring basis:

	September 30, 2012		December 31, 2011
(dollars in millions)
Foreign government bonds and notes	$	—	$	3.6
Forward currency contracts		0.7		(1.1	)
Option currency contracts		3.3		4.3
Interest rate swap contract		14.6		12.1

The fair values were measured using significant other observable inputs and valued by reference to similar financial instruments, adjusted for restrictions and other terms specific to each instrument. These financial instruments are categorized as Level 2 under the fair value hierarchy.

The fair value of the liability for contingent consideration related to prior acquisitions was $73.0 million and $77.1 million at September 30, 2012 and December 31, 2011, respectively. The fair value was measured using significant unobservable inputs and is categorized as Level 3 under the fair value hierarchy.

Financial Instruments not Measured at Fair Value

The fair value of commercial paper borrowings of $381.5 million and $304.5 million at September 30, 2012 and December 31, 2011, respectively, approximated carrying value. The company maintains a $600 million five-year committed syndicated bank credit facility that expires in October 2016. The credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit rating and includes a financial covenant that limits the amount of total debt to total capitalization.

The estimated fair value of long-term debt including the effect of the related interest rate swap contract was approximately $1.0 billion at both periods ended September 30, 2012 and December 31, 2011. The fair value was estimated using dealer quotes for similarly-rated debt instruments over the remaining contractual term of the company’s obligation. Long-term debt is categorized as Level 2 under the fair value hierarchy.

Concentration Risk

Accounts receivable balances include sales to government-supported healthcare systems outside the United States. The company continues to monitor sovereign debt issues and economic conditions in Europe and evaluates accounts receivable in certain countries for potential collection risks. Deteriorating economic conditions and other factors in certain countries in Europe have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these accounts receivable and may require the company to re-evaluate the collectability of these receivables in future periods. The company has experienced significant delays in the collection of accounts receivable associated with the national healthcare systems in Spain, Italy, Greece and Portugal. At September 30, 2012, the company’s accounts receivable, net of allowances, from the national healthcare systems in these countries and amounts past due greater than 365 days are as follows:

	Accounts receivable, net		Greater than 365 days past due
(dollars in millions)
Spain	$	14.2	$	1.3
Italy		26.8		4.5
Greece		11.9		3.8
Portugal (A)		3.7		0.6
	$	56.6	$	10.2

^(A)  Subsequent cash collections in the fourth quarter of 2012 were approximately $0.6 million, of which $0.2 million related to receivables greater than 365 days past due.

10

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

In March 2012, the Greek government approved a private sector bond exchange program for holders of Greek public debt, including those bonds held by the company. As a result, the company’s bonds were exchanged for a combination of new Greek government bonds and certain other notes. These bonds and notes were classified as available-for-sale securities and were reported at fair value. In July 2012, the company sold these bonds and notes.

7. Inventories

Inventories consisted of:

	September 30, 2012		December 31, 2011
(dollars in millions)
Finished goods	$	205.1	$	189.9
Work in process		20.1		21.3
Raw materials		110.7		108.0
	$	335.9	$	319.2

8. Contingencies

General

In the ordinary course of business, the company is subject to various legal proceedings and claims, including, for example, product liability matters, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant patent legal claims. The company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and reasonably estimable. Legal costs associated with these matters are expensed as incurred. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company was determined to be invalid or unenforceable, the company might be required to reduce the value of certain intangible assets on the company’s balance sheet and to record a corresponding charge, which could be significant in amount. The company believes that any of these proceedings and claims could have a material adverse effect on its business, results of operations, financial condition and/or liquidity.

Product Liability Matters

As of October 18, 2012, approximately 1,505 federal and 755 state lawsuits involving individual claims by approximately 2,400 plaintiffs, as well as two putative class actions in the United States and three putative class actions in various Canadian provinces, have been filed or asserted against the company with respect to its Composix^® Kugel^® and certain other hernia repair implant products (collectively, the “Hernia Product Claims”). One of the U.S. class action lawsuits consolidates ten previously-filed U.S. class action lawsuits. The putative class actions, none of which has been certified, seek (i) medical monitoring, (ii) compensatory damages, (iii) punitive damages, (iv) a judicial finding of defect and causation and/or (v) attorneys’ fees. Approximately 730 of the state lawsuits, involving individual claims by approximately 830 plaintiffs, are pending in the Superior Court of the State of Rhode Island, with the remainder in various other jurisdictions. The Hernia Product Claims also generally seek damages for personal injury resulting from use of the products. The company voluntarily recalled certain sizes and lots of the Composix^® Kugel^® products beginning in December 2005.

In June 2007, the Judicial Panel on Multidistrict Litigation (“JPML”) transferred Composix^® Kugel^® lawsuits pending in federal courts nationwide into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings in the United States District Court for the District of Rhode Island. The MDL court subsequently determined to include other hernia repair products of the company in the MDL proceeding. The first MDL trial was completed in April 2010 and resulted in a judgment for the company based on the jury’s finding that the company was not liable for the plaintiff’s damages. The second MDL trial was completed in August 2010 and resulted in a judgment for the plaintiff of $1.5 million. On June 30, 2011, the company announced that it had reached agreements in principle with various plaintiffs’ law firms to settle the majority of its existing Hernia Product Claims. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. In addition, the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Hernia Product Claims, and intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. Additional trials are

11

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

scheduled in the first quarter of 2013. Based on these events, the company recorded to other (income) expense, net, a charge of $184.3 million ($180.6 million after tax) in the second quarter of 2011, which recognized the estimated costs of settling all Hernia Product Claims, including asserted and unasserted claims, and costs to administer the settlements. The charge excludes any costs associated with pending putative class action lawsuits. The company cannot give any assurances that the actual costs incurred with respect to the Hernia Product Claims will not exceed the amount of the charge together with amounts previously accrued. The company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

As of October 18, 2012, product liability lawsuits involving individual claims by approximately 1,580 plaintiffs have been filed or asserted against the company in various federal and state jurisdictions alleging personal injuries associated with the use of certain of the company’s surgical continence products for women, principally its Avaulta^® line of products. In addition, four putative class actions in the United States and one putative class action in Canada have been filed against the company (all lawsuits, collectively, the “Women’s Health Product Claims”). The Women’s Health Product Claims generally seek damages for personal injury resulting from use of the products. The putative class actions, none of which has been certified, seek (i) medical monitoring, (ii) compensatory damages, (iii) punitive damages, (iv) a judicial finding of defect and causation and/or (v) attorneys’ fees. With respect to certain of these claims, the company believes that one of its suppliers has an obligation to defend and indemnify the company. In October 2010, the JPML transferred the Women’s Health Product Claims involving solely Avaulta^® products pending in federal courts nationwide into an MDL for coordinated pre-trial proceedings in the United States District Court for the Southern District of West Virginia. In February 2012, the JPML expanded the scope of and renamed the MDL pending in the United States District Court for the Southern District of West Virginia to include lawsuits involving all women’s surgical continence products that are manufactured or distributed by the company. In total, approximately 1,195 of the Women’s Health Product Claims are pending in federal courts and have been or will be transferred to the MDL in West Virginia, with the remainder of the Women’s Health Product Claims in other jurisdictions. Trial dates have been scheduled in the MDL beginning in March 2013. The first trial in one of these other jurisdictions was completed in July 2012 and resulted in a judgment against the company of approximately $3.6 million. The company has appealed this decision. The company does not believe that this verdict is representative of the potential outcomes of other Women’s Health Product Claims. While the company intends to vigorously defend the Women’s Health Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

As of October 18, 2012, product liability lawsuits involving individual claims by approximately 60 plaintiffs have been filed or asserted against the company in various federal and state jurisdictions alleging personal injuries associated with the use of the company’s vena cava filter products. In addition, three putative class actions have been filed against the company in various state courts on behalf of plaintiffs who are alleged to have no present injury (all lawsuits, collectively, the “Filter Product Claims”). The putative class actions, none of which has been certified, seek: (i) medical monitoring; (ii) punitive damages; (iii) a judicial finding of defect and causation; and/or (iv) attorneys’ fees. The first Filter Product Claim trial was completed in June 2012 and resulted in a judgment for the company based on the finding that the company was not liable for the plaintiff’s damages. The company expects additional trials of Filter Product Claims to take place over the next 12 months. While the company intends to vigorously defend the Filter Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In most product liability litigations of this nature, including the Hernia Product Claims, the Women’s Health Product Claims and the Filter Product Claims, plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions, and consequently, is unable to fully evaluate the claims. The company expects that it will receive and review additional information regarding the unsettled Hernia Product Claims, the Women’s Health Product Claims, the Filter Product Claims and related matters as these cases progress.

The company believes that many settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers. In certain circumstances, insurance carriers reserve their rights with respect to coverage, or contest or deny coverage, as has occurred with respect to certain claims. When this occurs, the company intends to vigorously contest disputes with respect to its insurance coverage and to enforce its rights under the terms of its insurance policies, and accordingly, will record receivables with respect to amounts due under these policies, when recovery is probable. Amounts

12

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

recovered under the company’s product liability insurance policies may be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.

The company’s insurance coverage with respect to the Hernia Product Claims has been depleted. In connection with the Hernia Product Claims, the company is in dispute with one of its excess insurance carriers relating to an aggregate of $25 million of insurance receivables.

In connection with the Women’s Health Product Claims, the company is in dispute with one of its excess insurance carriers relating to an aggregate of $50 million of insurance coverage.

Other Legal Matters

In November 2006, the company received a subpoena issued by the U.S. Department of Health and Human Services, Office of Inspector General (“OIG”), under the authority of the federal healthcare fraud and false claims statutes, seeking documents related to the company’s brachytherapy business (the “Brachytherapy Matter”). On January 27, 2012, the company announced that it had reached a preliminary agreement with the civil and criminal divisions of the United States Attorney’s Office for the Northern District of Georgia to resolve claims with respect to the Brachytherapy Matter. In connection with this preliminary agreement, the company recorded to other (income) expense, net, a charge of approximately $51.0 million ($40.8 million after tax) in the fourth quarter of 2011. The ultimate settlement of this matter is subject to the negotiation and execution of definitive agreements, which will likely include civil settlement and non-prosecution agreements, and a corporate integrity agreement with the OIG. If the definitive agreements are not finalized, the eventual costs related to this matter could be materially different than the previously recorded charge, and the company cannot give any assurances that this matter will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In December 2007, a U.S. District Court jury in Arizona found that certain of W.L. Gore & Associates Inc.’s (“Gore”) ePTFE vascular grafts and stent-grafts infringe the company’s patent number 6,436,135. The jury upheld the validity of the patent and awarded the company $185 million in past damages. The jury also found that Gore willfully infringed the patent. In a second phase of the trial, the District Court ruled that Gore failed to prove that the patent is unenforceable due to inequitable conduct. In March 2009, the District Court doubled the jury award to approximately $371 million for damages through June 2007. The District Court also awarded the company attorneys’ fees of $19 million and prejudgment interest of approximately $20 million. In addition, the District Court denied Gore’s remaining motions, including its motions for a new trial and to set aside the jury’s verdict. In July 2010, the District Court awarded the company approximately $109 million in additional damages for the period from July 2007 through March 2009. Gore has deposited or secured the foregoing amounts with the District Court. The District Court also assessed a royalty rate of between 12.5% and 20%, depending on the product, that will be used to calculate damages for Gore’s infringing sales from April 2009 through the expiration of the patent. Gore has made additional deposits with the District Court of approximately $401 million, representing Gore’s calculation of royalties for its infringing sales through June 2012. Gore appealed this matter to the Court of Appeals for the Federal Circuit (the “Court of Appeals”), which on February 10, 2012 affirmed the decision of the District Court. Gore filed a petition with the Court of Appeals for a rehearing of its appeal. On June 14, 2012, the Court of Appeals reaffirmed its February 10, 2012 decision, including the ongoing royalty rates as set by the District Court, with the exception of the issue of willfulness with respect to Gore’s infringement of Bard’s patent number 6,436,135, which was remanded to the District Court. On October 12, 2012, Gore filed a petition for a writ of certiorari to the U.S. Supreme Court requesting a review of the portion of the decision that the Court of Appeals reaffirmed. Since the company considers this matter a gain contingency, no amounts have been recorded. Even if the company is ultimately successful in this lawsuit, it cannot give any assurances that royalties for Gore’s future infringing sales will remain at or near historic levels.

The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under various federal laws including the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), commonly known as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state or foreign laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of

13

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

the parties to the site contamination. The company’s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined. Accruals for estimated losses from environmental remediation obligations generally are recognized no later than completion of the remedial feasibility study and are adjusted as further information develops or circumstances change. Costs of future expenditures for environmental remediation obligations are not discounted to their present value. Recoveries of environmental remediation costs from other parties are recorded as assets when their receipt is deemed probable. The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company’s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the company’s business and/or results of operations.

The company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.

Accruals for product liability and other legal matters amounted to $168.8 million and $287.3 million at September 30, 2012 and December 31, 2011, respectively. Through September 30, 2012, the company made payments of $155.4 million to qualified settlement funds (“QSFs”), of which $6.2 million were made during the nine months ended September 30, 2012, subject to certain settlement conditions, for certain Hernia Product Claims. Payments to QSFs were recorded as a component of restricted cash. Total payments of $127.9 million from these QSFs have been made to qualified claimants, of which $125.8 million were made during the nine months ended September 30, 2012. In addition, other payments of $8.0 million have been made to qualified claimants, of which $5.4 million were made during the nine months ended September 30, 2012.

The company recorded receivables from insurance companies for product liability matters amounting to $55.7 million and $51.0 million at September 30, 2012 and December 31, 2011, respectively, of which $30.0 million, at September 30, 2012, is the subject of the disputes with certain excess insurance carriers, as noted above. After considering the nature of the claims, coverage provisions under the policies, relevant legal issues, the advice and judgment of outside legal counsel, and other pertinent factors, the company believes its claims are meritorious and that it will collect these receivables.

The company is unable to estimate the reasonably possible losses or range of losses, if any, arising from certain existing product liability matters and other legal matters. Under U.S. generally accepted accounting principles, an event is “reasonably possible” if “the chance of the future event or events occurring is more than remote but less than likely” and an event is “remote” if “the chance of the future event or events occurring is slight”. With respect to the Women’s Health Product Claims, the Filter Product Claims and the putative class action lawsuits that are part of the Hernia Product Claims, the company is unable to estimate a range of reasonably possible losses for the following reasons: (i) the proceedings are in early stages; (ii) the company has not received and reviewed complete information regarding the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, with respect to the putative class action lawsuits that are part of the Hernia Product Claims and the Filter Product Claims, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class.

9. Share-Based Compensation Plans

The company may grant a variety of share-based payments under the 2012 Long Term Incentive Plan of C. R. Bard, Inc., as amended and restated (formerly the 2003 Long Term Incentive Plan of C. R. Bard, Inc., as amended and restated) (the “Plan”) and the 2005 Directors’ Stock Award Plan of C. R. Bard, Inc., as amended and restated (the “Directors’ Plan”) to certain directors, officers and employees. At the company’s Annual Meeting of Shareholders on April 18, 2012, the shareholders authorized an additional 2,750,000 shares for issuance under the Plan. In addition, shareholders approved an amendment modifying the structure of the Plan so that each stock option granted will reduce the number of total shares available under the Plan by one share, and each full-value share-based award will reduce the number of total shares available under the Plan by 2.87 shares. The total number of remaining shares at September 30, 2012 that may be issued under the Plan was 5,904,609 and under the Directors’ Plan was 49,099. Awards under the Plan may be in the form of stock options, stock appreciation rights, limited stock appreciation rights, restricted stock, unrestricted stock and other stock-based awards. Awards under the Directors’ Plan may be in the form of stock awards, stock options or stock appreciation rights. The company has two employee stock purchase programs. On April 18, 2012, the shareholders authorized an additional 750,000 shares for issuance under the Employee Stock Purchase Plan of C. R. Bard, Inc., as Amended and Restated (formerly the 1998 Employee Stock Purchase Plan of C. R. Bard, Inc., as Amended and Restated).

14

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Amounts recognized for share-based compensation are as follows:

	Quarter Ended September  30,						Nine Months  Ended September 30,
	2012			2011			2012			2011
(dollars in millions)
Total cost of share-based compensation plans	$	11.5		$	11.1		$	39.0		$	36.5
Amounts capitalized in inventory and fixed assets		(0.4	)		(0.3	)		(1.2	)		(1.0	)
Amounts recognized in income for amounts previously capitalized in inventory and fixed assets		0.4			0.3			1.2			1.2
Amounts charged against income	$	11.5		$	11.1		$	39.0		$	36.7

In the first quarter of 2012, the company granted performance restricted stock units to certain officers. These units have requisite service periods of three years and have no dividend rights. The actual payout of these units varies based on the company’s performance over the three-year period against pre-established targets, including a performance condition based on average earnings per share growth over the period and a market condition modifier based on total shareholder return (“TSR”) compared to an industry peer group. The actual payout under these awards may vary from zero to 200% of an officer’s target payout. Compensation cost initially recognized assumes that the target payout level will be achieved and is adjusted for subsequent changes in the expected outcome of the performance-related condition. The fair value of these units is based on the market price of the company’s stock on the date of grant and uses a Monte Carlo simulation model for the TSR component. The fair value of the TSR component was estimated based on the following assumptions: risk-free interest rate of 0.41%; dividend yield of 0.85%; and expected life of 2.83 years.

Anticipated purchases under the Management Stock Purchase Program (the “MSPP”) were approximately 0.2 million shares in each year presented and the fair value per share related to these purchases was $38.33 and $38.25, respectively. The fair values of the 2012 and 2011 annual MSPP purchases were estimated in July 2012 and July 2011, respectively, using the Black-Scholes model based on the following assumptions: risk-free interest rate of 0.16% and 0.12%, respectively; expected volatility of 20% and 16%, respectively; dividend yield of 0.9% and 0.8%, respectively; and expected life of 0.6 years for both valuations.

As of September 30, 2012, there were $78.3 million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately two years. The company has sufficient shares to satisfy expected share-based payment arrangements in 2012.

10. Pension and Other Postretirement Benefit Plans

Defined Benefit Pension Plans - The company has both tax-qualified and nonqualified, noncontributory defined benefit pension plans, that together cover certain domestic and foreign employees. These plans provide benefits based upon a participant’s compensation and years of service.

The components of net periodic pension cost are as follows:

	Quarter Ended September  30,						Nine Months  Ended September 30,
	2012			2011			2012			2011
(dollars in millions)
Service cost, net of employee contributions	$	7.0		$	6.8		$	20.8		$	20.3
Interest cost		4.9			4.8			14.6			14.2
Expected return on plan assets		(6.2	)		(5.9	)		(17.9	)		(17.6	)
Amortization		2.8			1.9			7.8			5.9
Net periodic pension cost	$	8.5		$	7.6		$	25.3		$	22.8

Other Postretirement Benefit Plan - The company does not provide subsidized postretirement healthcare benefits and life insurance coverage except for a limited number of former employees. As this plan is unfunded, contributions are made as benefits are incurred. The net periodic benefit cost was $0.2 million for both quarters ended September 30, 2012 and 2011. The net periodic benefit cost was $0.5 million for both of the nine month periods ended September 30, 2012 and 2011.

15

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

11. Shareholders’ Investment

The company repurchased approximately 3.8 million shares of common stock for $367.2 million during the nine months ended September 30, 2012 under two previously announced $500 million share repurchase programs.

Other Comprehensive Income (Loss)

On January 1, 2012, the company adopted Financial Accounting Standards Board amended guidance, with the exception of an amendment providing for a deferral of a certain provision, on the presentation of other comprehensive income and its components in the consolidated condensed financial statements. The company has elected to present net income and comprehensive income as two separate but consecutive statements. This guidance was applied retrospectively, as required.

The accumulated balances related to each component of other comprehensive income (loss) are as follows:

	Change in Derivative Instruments Designated As Cash Flow  Hedges			Foreign  Currency Translation Adjustment			Benefit  Plan Adjustments			Accumulated Other Comprehensive (Loss) Income
(dollars in millions)
Balance at December 31, 2011	$	(1.4	)	$	41.1		$	(106.3	)	$	(66.6	)
Other comprehensive income (loss) before income taxes		4.1			(24.3	)		8.0			(12.2	)
Income tax (provision) benefit related to other comprehensive income (loss) items (A)		(2.0	)		—			(2.8	)		(4.8	)
Balance at September 30, 2012	$	0.7		$	16.8		$	(101.1	)	$	(83.6	)
Balance at December 31, 2010	$	—		$	29.0		$	(85.2	)	$	(56.2	)
Other comprehensive income (loss) before income taxes		(6.7	)		41.9			6.0			41.2
Income tax (provision) benefit related to other comprehensive income (loss) items (A)		2.6			—			(2.1	)		0.5
Balance at September 30, 2011	$	(4.1	)	$	70.9		$	(81.3	)	$	(14.5	)

^(A)  Income taxes are not provided for foreign currency translation adjustments.

16

C. R. BARD, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

12. Segment Information

The company’s management considers its business to be a single segment entity—the manufacture and sale of medical devices. The company’s products generally share similar distribution channels and customers. The company designs, develops, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells a broad range of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities on a global basis. In general, the company’s products are intended to be used once and then discarded or either temporarily or permanently implanted. The company’s chief operating decision makers evaluate their various global product portfolios on a net sales basis and generally evaluate profitability and associated investment on an enterprise-wide basis due to shared geographic infrastructures.

Net sales based on the location of external customers by geographic region are:

	Quarter Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
(dollars in millions)
United States	$	483.4	$	486.5	$	1,469.6	$	1,453.5
Europe		115.6		124.2		369.3		380.3
Japan		41.6		36.1		122.2		103.9
Other		82.3		72.4		234.4		206.8
	$	722.9	$	719.2	$	2,195.5	$	2,144.5

Total net sales by product group category are:

	Quarter Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
(dollars in millions)
Vascular	$	202.5	$	208.2	$	633.0	$	621.7
Urology		188.1		182.2		562.0		544.4
Oncology		203.9		198.9		601.9		578.1
Surgical Specialties		107.7		107.6		333.8		333.4
Other		20.7		22.3		64.8		66.9
	$	722.9	$	719.2	$	2,195.5	$	2,144.5

Other information is:

	Quarter Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
(dollars in millions)
Depreciation	$	13.2	$	12.2	$	40.2	$	39.0
Amortization	$	20.4	$	15.4	$	61.2	$	45.4

17

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This management’s discussion and analysis provides a review of the results of operations, financial condition and the liquidity and capital resources of C. R. Bard and its subsidiaries (the “company” or “Bard”). The following discussion should be read in conjunction with Bard’s 2011 Annual Report on Form 10-K, and the condensed consolidated financial statements and notes thereto included elsewhere in this Form 10-Q. Certain statements contained herein may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995; see “Risks and Uncertainties; Cautionary Statement Regarding Forward-Looking Information” below.

Overview

The company designs, develops, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells a broad range of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities on a global basis. Outside the United States, Europe and Japan are the company’s largest markets, while certain emerging markets in Asia and Latin America are the company’s fastest growing markets. In general, the company’s products are intended to be used once and then discarded or either temporarily or permanently implanted. The company reports sales in four major product group categories: vascular; urology; oncology; and surgical specialties. The company also has a product group category of other products.

The company’s earnings are driven by its ability to continue to generate sales of its products and improve operating efficiency. Bard’s ability to increase sales over time depends upon its success in developing, acquiring and marketing differentiated products that meet the needs of clinicians and their patients. For the nine months ended September 30, 2012, the company’s research and development (“R&D”) expense as a percentage of net sales was 6.9%. The company expects R&D expense as a percentage of net sales to increase in future years. The company also makes selective acquisitions of businesses, products and technologies, generally focusing on small-to-medium sized transactions to provide ongoing growth opportunities. In addition, the company may from time-to-time consider acquisitions of larger, established companies. The company may also periodically divest lines of business in which it is not able to reasonably attain or maintain a leadership position in the market or for other strategic reasons.

Recent Developments

On October 19, 2012, the company acquired Neomend, Inc. (“Neomend”), a privately-held company engaged in the development and commercialization of innovative surgical sealants. The purchase consideration consists of an up front cash payment of $140 million and contingent consideration of up to $25 million, based on the achievement of sales-based milestone payments through 2016. Neomend’s products expand Bard’s existing surgical specialties product portfolio to include the only product approved by the U.S. Food and Drug Administration for the treatment of intraoperative air leaks in connection with thoracic surgery. Neomend’s proprietary technology and pipeline provides the opportunity for future clinical indications across a variety of surgical specialty applications. Substantially all of the purchase price for this acquisition was funded through the issuance of commercial paper.

Healthcare Reform

Significant reforms to the U.S. healthcare system were adopted in the form of the Patient Protection and Affordable Care Act of 2010 (the “PPACA”). The PPACA requires, among other things, the company to pay a 2.3% excise tax on most U.S. medical device sales beginning in 2013. While the company continues to evaluate the impact of this tax on its overall business, based on 2011 annual U.S. sales, the excise tax would have equated to approximately $44 million.

Results of Operations

Net Sales

Bard’s consolidated net sales for the quarter ended September 30, 2012 increased 1% on a reported basis (3% on a constant currency basis) compared to the same period in the prior year. Bard’s consolidated net sales for the nine months ended September 30, 2012 increased 2% on a reported basis (4% on a constant currency basis) compared to the same period in the prior year. Net sales “on a constant currency basis” is a non-GAAP measure and should not be viewed as a replacement of GAAP results. See “Management’s Use of Non-GAAP Measures” below. Price changes had the effect of decreasing consolidated net sales for the quarter and nine months ended September 30, 2012 by approximately 130 and 140 basis points, respectively, as compared to the same periods in the prior year. Exchange rate fluctuations had the effect of decreasing consolidated net sales for both the quarter and nine months ended September 30, 2012 by 2% as compared to the same periods in the prior year. The primary exchange rate movement that impacts net sales is the movement of the Euro compared to the U.S. dollar. The impact of exchange rate movements on net sales is not indicative of the impact on net earnings due to the offsetting impact of exchange rate movements on operating costs and expenses, costs incurred in other currencies and the company’s hedging activities.

18

Bard’s United States net sales of $483.4 million for the quarter ended September 30, 2012 decreased 1% compared to $486.5 million in the prior year quarter. Net sales in the United States have moderated in recent quarters, a trend that may continue. International net sales of $239.5 million for the quarter ended September 30, 2012 increased 3% on a reported basis (11% on a constant currency basis) compared to $232.7 million in the prior year quarter. Bard’s United States net sales of $1,469.6 million for the nine months ended September 30, 2012 increased 1% compared to $1,453.5 million in the prior year period. International net sales of $725.9 million for the nine months ended September 30, 2012 increased 5% on a reported basis (10% on a constant currency basis) compared to $691.0 million in the prior year period.

A summary of net sales by product group category is as follows:

Product Group Summary of Net Sales

	Quarter Ended September 30,									Nine Months Ended September 30,
	2012		2011		Change		Constant Currency			2012		2011		Change		Constant Currency
(dollars in millions)
Vascular	$	202.5	$	208.2		(3)%		1	%	$	633.0	$	621.7		2%		4	%
Urology		188.1		182.2		3%		5	%		562.0		544.4		3%		4	%
Oncology		203.9		198.9		3%		4	%		601.9		578.1		4%		5	%
Surgical Specialties		107.7		107.6		—		2	%		333.8		333.4		—		1	%
Other		20.7		22.3		(7)%		(6	)%		64.8		66.9		(3)%		(3	)%
Total net sales	$	722.9	$	719.2		1%		3	%	$	2,195.5	$	2,144.5		2%		4	%

Vascular Products - Bard markets a wide range of products for the peripheral vascular market, including endovascular products, electrophysiology products and vascular graft products. The decrease in consolidated net sales of vascular products for the quarter ended September 30, 2012 compared to the prior year period was due primarily to a decline in sales of electrophysiology products and vascular grafts. The increase in consolidated net sales of vascular products for the nine months ended September 30, 2012 compared to the prior year period was due primarily to an increase in sales of endovascular products partially offset by a decline in sales of electrophysiology and vascular graft products. United States net sales of vascular products for the quarter ended September 30, 2012 decreased 5% compared to the prior year quarter. International net sales of vascular products for the quarter ended September 30, 2012 increased 1% on a reported basis (11% on a constant currency basis) compared to the prior year quarter. United States net sales of vascular products for the nine months ended September 30, 2012 decreased 2% compared to the prior year period. International net sales of vascular products for the nine months ended September 30, 2012 increased 6% on a reported basis (13% on a constant currency basis) compared to the prior year period.

Consolidated net sales of endovascular products for the quarter ended September 30, 2012 were flat on a reported basis (increased 3% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of endovascular products for the nine months ended September 30, 2012 increased 5% on a reported basis (7% on a constant currency basis) compared to the prior year period. Stents and percutaneous transluminal angioplasty balloon catheters were the primary contributors to growth in this category for the nine months ended September 30, 2012. Net sales of stents for the quarter and nine months ended September 30, 2012 have benefited from an issue with the availability of a competitor’s products.

Consolidated net sales of electrophysiology products for the quarter ended September 30, 2012 decreased 10% on a reported basis (4% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of electrophysiology products for the nine months ended September 30, 2012 decreased 6% on a reported basis (2% on a constant currency basis) compared to the prior year period.

Consolidated net sales of vascular graft products for the quarter ended September 30, 2012 decreased 11% on a reported basis (6% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of vascular graft products for the nine months ended September 30, 2012 decreased 9% on a reported basis (6% on a constant currency basis) compared to the prior year period.

Urology Products - Bard markets a wide range of products for the urology market, including basic drainage products, continence products and urological specialty products. Bard also markets StatLock^® catheter stabilization products, which are used to secure many types of catheters sold by Bard and other companies. The majority of basic drainage products, StatLock^® catheter stabilization products and certain urological specialty products are sold through distributors. Bard also markets Targeted Temperature Management^™ products, acquired in November 2011, for therapeutic hypothermia. The increase in consolidated net sales of urology products for the quarter ended September 30, 2012 compared to the prior year period

19

included 5 percentage points of growth on a reported basis (6 percentage points of growth on a constant currency basis) from the addition of Targeted Temperature Management^™ products. This growth was partially offset by declines in sales of urological specialty products, StatLock^® catheter stabilization products and continence products, a trend that may continue. The increase in consolidated net sales of urology products for the nine months ended September 30, 2012 compared to the prior year period included 5 percentage points of growth on both a reported basis and constant currency basis from the addition of Targeted Temperature Management™ products. This growth was partially offset by declines in sales of urological specialty products and continence products, a trend that may continue. United States net sales of urology products for the quarter ended September 30, 2012 increased 3% compared to the prior year quarter. International net sales of urology products for the quarter ended September 30, 2012 increased 3% on a reported basis (9% on a constant currency basis) compared to the prior year quarter. United States net sales of urology products for the nine months ended September 30, 2012 increased 3% compared to the prior year period. International net sales of urology products for the nine months ended September 30, 2012 increased 3% on a reported basis (7% on a constant currency basis) compared to the prior year period.

Consolidated net sales of basic drainage products for the quarter ended September 30, 2012 were flat on a reported basis (increased 1% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of infection control Foley catheter products for the quarter ended September 30, 2012 decreased 1% on a reported basis (were flat on a constant currency basis) compared to the prior year quarter. Consolidated net sales of basic drainage products for the nine months ended September 30, 2012 were flat on a reported basis (increased 1% on a constant currency basis) compared to the prior year period. Consolidated net sales of infection control Foley catheter products for the nine months ended September 30, 2012 decreased 2% on both a reported basis and constant currency basis compared to the prior year period.

Consolidated net sales of urological specialty products, which include brachytherapy products, for the quarter ended September 30, 2012 decreased 9% on a reported basis (5% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of brachytherapy products for the quarter ended September 30, 2012 decreased 19% on a reported basis (14% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of urological specialty products for the nine months ended September 30, 2012 decreased 7% on a reported basis (5% on a constant currency basis) compared to the prior year period. Consolidated net sales of brachytherapy products for the nine months ended September 30, 2012 decreased 12% on a reported basis (9% on a constant currency basis) compared to the prior year period. The brachytherapy market has been losing procedural share to alternative therapies, a trend that may continue.

Consolidated net sales of continence products for the quarter ended September 30, 2012 decreased 3% on a reported basis (were flat on a constant currency basis) compared to the prior year quarter due primarily to a decline in sales of surgical continence products, a trend that may continue. Consolidated net sales of continence products for the nine months ended September 30, 2012 decreased 9% on a reported basis (7% on a constant currency basis) compared to the prior year period due primarily to the discontinuation of sales of a bulking continence product and a decline in sales of surgical continence products, a trend that may continue.

Consolidated net sales of the StatLock^® catheter stabilization product line for the quarter ended September 30, 2012 decreased 4% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of the StatLock^® catheter stabilization product line for the nine months ended September 30, 2012 decreased 2% on a reported basis (1% on a constant currency basis) compared to the prior year period.

Oncology Products - Bard’s oncology business includes specialty vascular access products and enteral feeding devices. Specialty vascular access products include peripherally inserted central catheters (“PICCs”) used for intermediate to long-term central venous access, specialty access ports and accessories (“Ports”) used most commonly for chemotherapy, dialysis access catheters and vascular access ultrasound devices which help facilitate the placement of PICCs. Consolidated net sales of oncology products for the quarter and nine months ended September 30, 2012 increased compared to the prior year periods due primarily to growth in sales of PICCs. United States net sales of oncology products for the quarter ended September 30, 2012 increased 1% compared to the prior year quarter. International net sales of oncology products for the quarter ended September 30, 2012 increased 6% on a reported basis (12% on a constant currency basis) compared to the prior year quarter. United States net sales of oncology products for the nine months ended September 30, 2012 increased 3% compared to the prior year period. International net sales of oncology products for the nine months ended September 30, 2012 increased 7% on a reported basis (11% on a constant currency basis) compared to the prior year period.

Consolidated net sales of PICCs for the quarter ended September 30, 2012 increased 5% on both a reported basis and constant currency basis compared to the prior year quarter. Consolidated net sales of Ports for the quarter ended September 30, 2012 were flat on a reported basis (increased 2% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of PICCs for the nine months ended September 30, 2012 increased 6% on a reported basis (7% on a constant currency basis) compared to the prior year period. Consolidated net sales of Ports for the nine months ended September 30, 2012 increased 1% on a reported basis (2% on a constant currency basis) compared to the prior year period.

20

Consolidated net sales of dialysis access catheters for the quarter ended September 30, 2012 increased 1% on a reported basis (3% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of vascular access ultrasound devices for the quarter ended September 30, 2012 increased 2% on a reported basis (3% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of dialysis access catheters for the nine months ended September 30, 2012 increased 1% on a reported basis (2% on a constant currency basis) compared to the prior year period. Consolidated net sales of vascular access ultrasound devices for the nine months ended September 30, 2012 increased 8% on a reported basis (9% on a constant currency basis) compared to the prior year period.

Surgical Specialty Products - Surgical specialty products include soft tissue repair, performance irrigation and hemostasis product lines. United States net sales of surgical specialty products for the quarter ended September 30, 2012 decreased 2% compared to the prior year quarter. International net sales of surgical specialty products for the quarter ended September 30, 2012 increased 6% on a reported basis (13% on a constant currency basis) compared to the prior year quarter. United States net sales of surgical specialty products for the nine months ended September 30, 2012 were flat compared to the prior year period. International net sales of surgical specialty products for the nine months ended September 30, 2012 increased 2% on a reported basis (6% on a constant currency basis) compared to the prior year period.

The soft tissue repair product line includes synthetic and natural-tissue hernia repair implants, natural-tissue breast reconstruction implants and hernia fixation products. Consolidated net sales of soft tissue repair products for the quarter ended September 30, 2012 were flat on a reported basis (increased 2% on a constant currency basis) compared to the prior year quarter. Consolidated net sales of soft tissue repair products for the nine months ended September 30, 2012 increased 1% on a reported basis (2% on a constant currency basis) compared to the prior year period. Net sales in this product line for the quarter and nine months ended September 30, 2012 were favorably impacted by growth in sales of synthetic hernia repair implants and natural-tissue breast reconstruction implants. This growth was offset by declines in natural-tissue hernia repair implants and hernia fixation products, a trend that may continue.

Other Products - The other product group includes irrigation, wound drainage and certain original equipment manufacturers’ products.

Costs and Expenses

A summary of costs and expenses as a percentage of net sales is as follows:

	Quarter Ended September  30,						Nine Months  Ended September 30,
	2012			2011			2012(A)			2011
Cost of goods sold		37.7	%		38.2	%		38.2	%		38.0	%
Marketing, selling and administrative expense		27.2	%		26.3	%		27.5	%		27.1	%
Research and development expense		7.2	%		6.5	%		6.9	%		6.6	%
Interest expense		1.3	%		1.3	%		1.3	%		1.3	%
Other (income) expense, net		1.9	%		2.4	%		0.9	%		9.8	%
Total costs and expenses		75.3	%		74.7	%		74.7	%		82.8	%

^(A)  Amounts do not add due to rounding.

Cost of goods sold - Cost of goods sold consists principally of the manufacturing and distribution costs of the company’s products. The category also includes royalties, amortization of intangible assets and the impact of certain hedging activities. Cost of goods sold as a percentage of net sales for the quarter ended September 30, 2012 decreased 50 basis points compared to the prior year quarter. Cost of goods sold as a percentage of net sales for the nine months ended September 30, 2012 increased 20 basis points compared to the prior year period. Incremental amortization of intangible assets acquired in 2011 and 2012 increased the cost of goods sold as a percentage of net sales by approximately 70 basis points over both the prior year quarter and nine month period. This increase was offset by cost improvements.

Marketing, selling and administrative expense - Marketing, selling and administrative expense consists principally of the costs associated with the company’s sales and administrative organizations. These costs as a percentage of net sales for the quarter and nine months ended September 30, 2012 increased 90 basis points and 40 basis points, respectively, compared to the prior year periods. These costs as a percentage of net sales increased primarily due to related costs from operations acquired in 2011 and continued investments in emerging markets.

Research and development expense - Research and development expense consists principally of costs related to internal research and development activities, milestone payments for third-party research and development activities, and acquired in-process R&D (“IPR&D”) costs arising from the company’s business development activities. IPR&D payments

21

may impact the comparability of the company’s results of operations between periods. Research and development expense for the quarter ended September 30, 2012 was $52.2 million, an increase of approximately 11% compared to the prior year quarter. Research and development expense for the nine months ended September 30, 2012 was $150.5 million, an increase of approximately 6% compared to the prior year period. An IPR&D charge of $2.0 million was recorded for the quarter and nine months ended September 30, 2012. IPR&D charges of $0.5 million and $3.5 million were recorded for the quarter and nine months ended September 30, 2011, respectively.

Interest expense - Interest expense was $9.7 million and $9.0 million for the quarters ended September 30, 2012 and 2011, respectively. Interest expense was $28.9 million and $27.1 million for the nine months ended September 30, 2012 and 2011, respectively.

Other (income) expense, net - The components of other (income) expense, net, are as follows:

	Quarter Ended September  30,						Nine Months  Ended September 30,
	2012			2011			2012			2011
(dollars in millions)
Interest income	$	(1.0	)	$	(1.2	)	$	(4.6	)	$	(3.1	)
Foreign exchange (gains) and losses		(1.0	)		0.8			(0.6	)		0.9
Asset impairments		13.2			—			22.2			—
Restructuring		—			10.0			(1.6	)		8.9
Impairment charge for bonds		—			7.0			—			7.0
Legal settlements and commitments		—			—			—			195.5
Other, net		2.4			0.4			3.6			2.0
Total other (income) expense, net	$	13.6		$	17.0		$	19.0		$	211.2

Asset impairments - For the quarter and nine months ended September 30, 2012, the amounts reflect a charge for the write-down of certain core technologies associated with a non-strategic product in the company’s vascular product group. In addition, the amount for the nine months ended September 30, 2012 reflects impairments of assets not related to operations.

Restructuring - For the nine months ended September 30, 2012, the amount reflects the reversal of certain restructuring costs recognized in the second half of 2011 (see Note 3 of the notes to the condensed consolidated financial statements). For the quarter and nine months ended September 30, 2011, the amounts reflect restructuring costs and the reversal of certain restructuring costs recognized in the second half of 2010.

Impairment charge for bonds - For the quarter and nine months ended September 30, 2011, the amount reflects other-than-temporary impairment of Greek bonds.

Legal settlements and commitments - For the nine months ended September 30, 2011, the amount reflects the estimated costs of settling all Hernia Product Claims (other than the putative class action lawsuits), including costs to administer the settlements, (see Note 8 of the notes to condensed consolidated financial statements) and certain other legal settlements and commitments.

Income Tax Provision

The effective tax rate for the quarter ended September 30, 2012 was approximately 27%, compared to approximately 29% for the same period in 2011. The effective tax rate for the nine months ended September 30, 2012 was approximately 28% compared to approximately 42% for the same period in 2011. The higher effective tax rate for the prior nine month period reflected the discrete tax effect of a charge for legal settlements, primarily related to Hernia Product Claims, which were incurred in a low tax jurisdiction.

Net Income and Earnings Per Share Available to Common Shareholders

The company reported net income and diluted earnings per share available to common shareholders for the quarter ended September 30, 2012 of $129.3 million and $1.50, respectively. Net income and diluted earnings per share available to common shareholders for the quarter ended September 30, 2011 was $130.1 million and $1.46, respectively. The current year quarter reflects asset impairments of $8.0 million, or $0.09 per diluted share, and acquisition-related items, primarily consisting of an IPR&D charge and transaction costs, of $4.1 million, or $0.05 per diluted share. The prior year quarter reflects an impairment charge for Greek bonds of $7.0 million, or $0.08 per diluted share, net restructuring costs of $6.7 million, or $0.08 per diluted share, and acquisition-related items, primarily consisting of transaction costs and an IPR&D charge, of $2.2 million, or $0.03 per diluted share. The prior year quarter also reflects a decrease to the income tax provision of $1.1 million or $0.01 per diluted share, due to an audit adjustment.

22

The company reported net income and diluted earnings per share available to common shareholders for the nine months ended September 30, 2012 of $401.9 million and $4.64, respectively. Net income and diluted earnings per share available to common shareholders for the nine months ended September 30, 2011 was $214.2 million and $2.40, respectively. The current nine month period reflects asset impairments of $13.8 million, or $0.16 per diluted share, acquisition-related items, primarily consisting of an IPR&D charge, transaction costs, purchase accounting adjustments and integration costs, of $5.7 million, or $0.07 per diluted share, and a reversal of certain restructuring costs of $1.1 million, or $0.01 per diluted share. The current nine month period also reflects an increase to the income tax provision of $1.1 million, or $0.01 per diluted share, due to the write-down of a tax receivable in a foreign jurisdiction. The prior nine month period reflects legal settlements and commitments of $189.5 million, or $2.12 per diluted share, an impairment charge for Greek bonds of $7.0 million, or $0.08 per diluted share, and net restructuring costs of $5.9 million, or $0.07 per diluted share. The prior nine month period also reflects acquisition-related items, primarily consisting of transaction costs and IPR&D charges, of $4.8 million, or $0.06 per diluted share and a decrease to the income tax provision of $1.1 million, or $0.01 per diluted share, due to an audit adjustment.

Liquidity and Capital Resources

The company assesses its liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. Significant factors affecting the management of liquidity are cash flows generated from operating activities, capital expenditures, acquisitions of businesses and technologies, cash dividends and common stock repurchases. Cash provided from operations continues to be a primary source of funds. The company believes that it could borrow adequate funds at competitive terms should it be necessary. The company also believes that its overall financial strength gives it sufficient financial flexibility. A summary of certain liquidity measures for Bard as of September 30 is as follows:

	2012		2011
(dollars in millions)
Working capital	$	1,000.7	$	1,392.8
Current ratio		2.28/1		3.74/1

Cash and cash equivalents held by the company’s foreign subsidiaries were $805.8 million and $586.9 million at September 30, 2012 and December 31, 2011, respectively. It is the company’s intention to permanently reinvest the majority of these funds outside the United States to finance foreign operations, and the company’s plans do not demonstrate a need to repatriate these funds. If these funds are needed for U.S. operations or can no longer be permanently reinvested outside the United States, the company would be required to accrue and pay U.S. taxes on the earnings associated with these funds. In the United States, ongoing operating cash flows and available borrowings under the company’s committed syndicated bank credit facility provide it with sufficient liquidity.

For the nine months ended September 30, 2012 and 2011, net cash provided by operating activities was $427.2 million and $549.4 million, respectively. The decrease in net cash provided by operating activities reflects current year payments to claimants for Hernia Product Claims settled in 2011.

For the nine months ended September 30, 2012, net cash provided by investing activities was $60.0 million compared to the $266.8 million used in cash for investing activities in the prior year period. Capital expenditures were approximately $55.5 million and $49.9 million for the nine month periods ended September 30, 2012 and 2011, respectively. Net cash provided by investing activities in the current period reflects an increase of $119.6 million related to the release of restricted cash from qualified settlement funds to claimants pursuant to the 2011 settlement of certain Hernia Product Claims.

For the nine months ended September 30, 2012, the company used $269.8 million in cash for financing activities, compared to the $166.1 million used in the prior year period. Total debt was $1.3 billion and $1.2 billion at September 30, 2012 and December 31, 2011, respectively. Total debt to total capitalization was 40.5% at both September 30, 2012 and December 31, 2011. The company spent approximately $372.5 million to repurchase 3,876,516 shares of common stock in the nine months ended September 30, 2012 compared to approximately $96.2 million to repurchase 1,068,200 shares of common stock in prior year period. Purchases of common stock for the nine months ended September 30, 2011 included a payment of $58.9 million in cash remitted to the bank counterparty upon final settlement under an accelerated share repurchase agreement. The company paid cash dividends of $0.58 per share and $0.55 per share for the nine month periods ended September 30, 2012 and 2011, respectively.

23

The company maintains a $600 million five-year committed syndicated bank credit facility that expires in October 2016. The credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit rating and includes a financial covenant that limits the amount of total debt to total capitalization. The company had outstanding commercial paper borrowings of $381.5 million and $304.5 million at September 30, 2012 and December 31, 2011, respectively.

Contingencies

In the ordinary course of business, the company is subject to various legal proceedings and claims, including product liability matters, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant patent legal claims. At any given time in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. See Note 8 of the notes to condensed consolidated financial statements.

Management’s Use of Non-GAAP Measures

Net sales “on a constant currency basis” is a non-GAAP measure. The company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, the company believes that evaluating growth in net sales on a constant currency basis provides an additional and meaningful assessment of net sales to both management and the company’s investors. Constant currency growth rates are calculated by translating the prior year’s local currency sales by the current period’s exchange rate. Constant currency growth rates are not indicative of changes in corresponding cash flows. The limitation of these non-GAAP measures is that they do not reflect results on a standardized reporting basis. Non-GAAP measures are intended to supplement the applicable GAAP disclosures and should not be viewed as replacements of GAAP results.

Critical Accounting Policies

The preparation of financial statements requires the company’s management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that require application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Such policies are summarized in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section in Bard’s 2011 Annual Report on Form 10-K. There have been no significant changes to the company’s critical accounting policies since December 31, 2011.

Risks and Uncertainties; Cautionary Statement Regarding Forward-Looking Information

Certain statements contained herein or in other company documents and certain statements that may be made by management of the company orally may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “forecast,” “plan,” “believe” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to product approvals, future performance of current and anticipated products, sales efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. The company’s forward-looking statements speak only as of the date of this report or as of the date they are made, and the company undertakes no obligation to update its forward-looking statements.

In addition, there are substantial risks inherent in the medical device business. The company’s business involves the design, development, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. These devices are often used on, or permanently or temporarily implanted in patients in clinically demanding circumstances, such as operating rooms, emergency units, intensive care and critical care settings, among others. These circumstances, among other factors, can cause the products to become associated with adverse clinical events, including patient mortality and injury, and could lead to product liability claims (including lawsuits seeking class action status or seeking to establish multi-district litigation proceedings) and other litigation, product withdrawals, warning letters, recalls, field corrections or regulatory enforcement actions relating to one or more of the company’s products, any of which could have a material adverse effect on our business, results of operations, financial condition and/or liquidity. For further discussion of risks applicable to our business, see “Risk Factors” in Bard’s 2011 Annual Report on Form 10-K.

24

Because actual results are affected by these and other risks and uncertainties, the company cautions investors that actual results may differ materially from those expressed or implied. It is not possible to predict or identify all risks and uncertainties. In addition to the risks addressed above and those described in the “Risk Factors” in Bard’s 2011 Annual Report on Form 10-K, certain other risks could adversely affect our business or cause the actual results to differ materially from those expressed or implied including, but not limited to:

Effective management of and reaction to risks involved in our business, including:

• the ability to achieve manufacturing or administrative efficiencies, including gross margin benefits from our manufacturing processes and supply chain programs or in connection with the integration of acquired businesses;

• the effects of negative publicity concerning our products, which could result in product withdrawals or decreased product demand and which could reduce market or governmental acceptance of our products;

• the ability to identify appropriate companies, businesses and technologies as potential acquisition candidates, to consummate and successfully integrate such transactions or to obtain agreements for such transactions on favorable terms;

• the reduction in the number of procedures using our devices caused by customers’ cost-containment pressures or preferences for alternate therapies;

• the ability to maintain or increase research and development expenditures;

• the uncertainty of whether increased research and development expenditures and sales force expansion will result in increased sales;

• the ability to reduce exposure and uncertainty related to tax audits, appeals and litigation;

• internal factors, such as retention of key employees, including sales force employees;

• the ability to achieve earnings forecasts, which are generated based, among other things, on projected volumes and sales of many product types, some of which are more profitable than others;

• changes in factors and assumptions or actual results that differ from our assumptions on stock valuation and employee stock option exercise patterns, which could cause compensation expense recorded in future periods to differ significantly from the compensation expense recorded in the current period;

• changes in factors and assumptions could cause pension cost recorded in future periods to differ from the pension cost recorded in the current period;

• the effect of market fluctuations on the value of assets in the company’s pension plans and the possibility that the company may need to make additional contributions to the plans as a result of any decline in the fair value of such assets;

• damage to a facility where our products are manufactured or from which they are distributed, which could render the company unable to manufacture or distribute one or more products and may require the company to reduce the output of products at the damaged facility thereby making it difficult to meet product shipping targets;

• the potential impairment of goodwill and intangible assets of the company resulting from insufficient cash flow generated from such assets specifically, or our business more broadly, so as to not allow the company to justify the carrying value of the assets;

• the ability to obtain appropriate levels of product liability insurance on reasonable terms;

• the ability to recover for claims made to our insurance companies; and

• the ability to realize the anticipated benefits of the 2011 restructuring activities to improve the company’s overall cost structure and improve efficiency.

Competitive factors, including:

• the trend of consolidation in the medical device industry as well as among our customers, resulting in potentially greater pricing pressures and more significant and complex contracts than in the past, both in the United States and abroad;

• development of new products or technologies by competitors having superior performance compared to our current products or products under development which could negatively impact sales of our products or render one or more of our products obsolete;

25

• technological advances, patents and registrations obtained by competitors that would have the effect of excluding the company from new market segments or preventing the company from selling a product or including key features in the company’s products;

• attempts by competitors to gain market share through aggressive marketing programs; and

• reprocessing by third-party reprocessors of our products designed and labeled for single use.

Difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, including:

• the ability to complete planned and/or ongoing clinical trials successfully, to develop and obtain regulatory approval for products on a timely basis and to launch products on a timely basis within cost estimates;

• lengthy and costly regulatory approval processes, which may result in lost market opportunities and/or delayed product launches;

• delays or denials of, or grants of low or reduced levels of reimbursement for, procedures using newly developed products;

• the suspension or revocation of authority to manufacture, market or distribute existing products;

• the imposition of additional or different regulatory requirements, such as those affecting manufacturing and labeling;

• performance, efficacy or safety concerns for existing products, whether scientifically justified or not, that may lead to product discontinuations, product withdrawals, recalls, field corrections, regulatory enforcement actions, litigation or declining sales, including adverse events and/or concerns relating to the company’s vena cava filters, pelvic floor repair products and hernia repair products;

• FDA inspections resulting in Form-483 notices and/or warning letters identifying deficiencies in the company’s manufacturing practices and/or quality systems; warning letters identifying violations of FDA regulations that could result in product holds, recalls, restrictions on future clearances by the FDA and/or civil penalties;

• the failure to obtain, limitations on the use of, or the loss of, patent and other intellectual property rights, and the failure of efforts to protect our intellectual property rights against infringement and legal challenges that can increase our costs;

• difficulties obtaining necessary components or raw materials used in the company’s products and/or price increases from the company’s suppliers of critical components or raw materials, including oil-based resins, or other interruptions of the supply chain; and

• customers that may limit the number of manufacturers or vendors from which they will purchase products, which can result in the company’s inability to sell products to or contract with large hospital systems, integrated delivery networks or group purchasing organizations.

Governmental action, including:

• the impact of continued healthcare cost containment;

• new laws and judicial decisions related to healthcare availability, healthcare reform, payment for healthcare products and services or the marketing and distribution of products, including legislative or administrative reforms to the United States Medicare and Medicaid systems or other United States or international reimbursement systems in a manner that would significantly reduce or eliminate reimbursements for procedures that use the company’s products;

• changes in the FDA and/or foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity;

• the impact of more vigorous compliance and enforcement activities affecting the healthcare industry in general or the company in particular;

• changes in the tax laws affecting our business, such as the excise tax in Puerto Rico;

• changes in the environmental laws or standards affecting our business;

• changes in laws that could require facility upgrades or process changes and could affect production rates and output; and

• compliance costs and potential penalties and remediation obligations in connection with environmental laws, including regulations regarding air emissions, waste water discharges and solid waste.

26

Legal disputes, including:

• disputes over intellectual property rights;

• product liability claims, which may involve lawsuits seeking class action status or seeking to establish multi-district litigation proceedings, including the Hernia Product Claims, the Women’s Health Product Claims and the Filter Product Claims;

• claims asserting securities law violations;

• claims asserting, and/or subpoenas seeking information regarding, violations of law in connection with federal and/or state healthcare programs such as Medicare or Medicaid;

• derivative shareholder actions;

• claims and subpoenas asserting antitrust violations;

• environmental claims, including risks relating to accidental contamination or injury from the use of hazardous materials in the company’s manufacturing, sterilization and research activities and the potential for the company to be held liable for any resulting damages; and

• commercial disputes, including disputes over distribution agreements, license agreements, manufacturing/supply agreements, development/research agreements, acquisition or sale agreements, and insurance policies.

General economic conditions, including:

• international and domestic business conditions;

• political or economic instability in foreign countries;

• interest rates;

• foreign currency exchange rates;

• changes in the rate of inflation; and

• instability of global financial markets and economies including Greece, Italy, Spain, Portugal and other countries in Europe.

Other factors beyond our control, including catastrophes, both natural and man-made, earthquakes, floods, fires, explosions, acts of terrorism or war.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The quantitative and qualitative disclosures about market risk are discussed in “Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in Bard’s 2011 Annual Report on Form 10-K. There have been no material changes in the information reported since the year ended December 31, 2011.

Item 4. Controls and Procedures

The company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the company’s reports under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosures. Any controls and procedures, no matter how well defined and operated, can provide only reasonable assurance of achieving the desired control objectives.

The company’s management, with the participation of the company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of the company’s disclosure controls and procedures as of September 30, 2012. Based upon that evaluation, the company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2012, the design and operation of the company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective to accomplish their objectives at the reasonable assurance level. There have been no changes in internal control over financial reporting for the quarter ended September 30, 2012 that have materially affected, or are likely to materially affect, the company’s internal control over financial reporting.

27

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

General

In the ordinary course of business, the company is subject to various legal proceedings and claims, including, for example, product liability matters, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant patent legal claims. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company was determined to be invalid or unenforceable, the company might be required to reduce the value of certain intangible assets on the company’s balance sheet and to record a corresponding charge, which could be significant in amount. The company believes that any of these proceedings and claims could have a material adverse effect on its business, results of operations, financial condition and/or liquidity.

Product Liability Matters

As of October 18, 2012, approximately 1,505 federal and 755 state lawsuits involving individual claims by approximately 2,400 plaintiffs, as well as two putative class actions in the United States and three putative class actions in various Canadian provinces, have been filed or asserted against the company with respect to its Composix^® Kugel^® and certain other hernia repair implant products (collectively, the “Hernia Product Claims”). One of the U.S. class action lawsuits consolidates ten previously-filed U.S. class action lawsuits. The putative class actions, none of which has been certified, seek (i) medical monitoring, (ii) compensatory damages, (iii) punitive damages, (iv) a judicial finding of defect and causation and/or (v) attorneys’ fees. Approximately 730 of the state lawsuits, involving individual claims by approximately 830 plaintiffs, are pending in the Superior Court of the State of Rhode Island, with the remainder in various other jurisdictions. The Hernia Product Claims also generally seek damages for personal injury resulting from use of the products. The company voluntarily recalled certain sizes and lots of the Composix^® Kugel^® products beginning in December 2005.

In June 2007, the Judicial Panel on Multidistrict Litigation (“JPML”) transferred Composix^® Kugel^® lawsuits pending in federal courts nationwide into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings in the United States District Court for the District of Rhode Island. The MDL court subsequently determined to include other hernia repair products of the company in the MDL proceeding. The first MDL trial was completed in April 2010 and resulted in a judgment for the company based on the jury’s finding that the company was not liable for the plaintiff’s damages. The second MDL trial was completed in August 2010 and resulted in a judgment for the plaintiff of $1.5 million. On June 30, 2011, the company announced that it had reached agreements in principle with various plaintiffs’ law firms to settle the majority of its existing Hernia Product Claims. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. In addition, the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Hernia Product Claims, and intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. Additional trials are scheduled in the first quarter of 2013. Based on these events, the company incurred a charge of $184.3 million ($180.6 million after tax) in the second quarter of 2011, which recognized the estimated costs of settling all Hernia Product Claims, including asserted and unasserted claims, and costs to administer the settlements. The charge excludes any costs associated with pending putative class action lawsuits. The company cannot give any assurances that the actual costs incurred with respect to the Hernia Product Claims will not exceed the amount of the charge together with amounts previously accrued. The company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity. For more information, see Item 1A. “Risk Factors” in the company’s 2011 Annual Report on Form 10-K.

As of October 18, 2012, product liability lawsuits involving individual claims by approximately 1,580 plaintiffs have been filed or asserted against the company in various federal and state jurisdictions alleging personal injuries associated with the use of certain of the company’s surgical continence products for women, principally its Avaulta^® line of products. In addition, four putative class actions in the United States and one putative class action in Canada have been filed against the company (all lawsuits, collectively, the “Women’s Health Product Claims”). The Women’s Health Product Claims generally seek damages for personal injury resulting from use of the products. The putative class actions, none of which has been certified, seek (i) medical monitoring, (ii) compensatory damages, (iii) punitive damages, (iv) a judicial finding of defect and causation and/or (v) attorneys’ fees. With respect to certain of these claims, the company believes that one of its suppliers has an obligation to defend and indemnify the company. In October 2010, the JPML transferred the Women’s Health Product

28

Claims involving solely Avaulta^® products pending in federal courts nationwide into an MDL for coordinated pre-trial proceedings in the United States District Court for the Southern District of West Virginia. In February 2012, the JPML expanded the scope of and renamed the MDL pending in the United States District Court for the Southern District of West Virginia to include lawsuits involving all women’s surgical continence products that are manufactured or distributed by the company. In total, approximately 1,195 of the Women’s Health Product Claims are pending in federal courts and have been or will be transferred to the MDL in West Virginia, with the remainder of the Women’s Health Product Claims in other jurisdictions. Trial dates have been scheduled in the MDL beginning in February 2013. The first trial in one of these other jurisdictions was completed in July 2012 and resulted in a judgment against the company of approximately $3.6 million. The company has appealed this decision. The company does not believe that this verdict is representative of the potential outcomes of other Women’s Health Product Claims. While the company intends to vigorously defend the Women’s Health Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

As of October 18, 2012, product liability lawsuits involving individual claims by approximately 60 plaintiffs have been filed or asserted against the company in various federal and state jurisdictions alleging personal injuries associated with the use of the company’s vena cava filter products. In addition, three putative class actions have been filed against the company in various state courts on behalf of plaintiffs who are alleged to have no present injury (all lawsuits, collectively, the “Filter Product Claims”). The putative class actions, none of which has been certified, seek: (i) medical monitoring; (ii) punitive damages; (iii) a judicial finding of defect and causation; and/or (iv) attorneys’ fees. The first Filter Product Claim trial was completed in June 2012 and resulted in a judgment for the company based on the finding that the company was not liable for the plaintiff’s damages. The company expects additional trials of Filter Product Claims to take place over the next 12 months. While the company intends to vigorously defend the Filter Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In most product liability litigations of this nature, including the Hernia Product Claims, the Women’s Health Product Claims and the Filter Product Claims, plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions, and consequently, is unable to fully evaluate the claims. The company expects that it will receive and review additional information regarding the unsettled Hernia Product Claims, the Women’s Health Product Claims, the Filter Product Claims and related matters as these cases progress.

The company believes that many settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers. In certain circumstances, insurance carriers reserve their rights with respect to coverage, or contest or deny coverage, as has occurred with respect to certain claims. When this occurs, the company intends to vigorously contest disputes with respect to its insurance coverage and to enforce its rights under the terms of its insurance policies, and accordingly, will record receivables with respect to amounts due under these policies, when recovery is probable. Amounts recovered under the company’s product liability insurance policies may be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.

The company’s insurance coverage with respect to the Hernia Product Claims has been depleted. In connection with the Hernia Product Claims, the company is in dispute with one of its excess insurance carriers relating to an aggregate of $25 million of insurance receivables.

In connection with the Women’s Health Product Claims, the company is in dispute with one of its excess insurance carriers relating to an aggregate of $50 million of insurance coverage.

Other Legal Matters

In November 2006, the company received a subpoena issued by the U.S. Department of Health and Human Services, Office of Inspector General (“OIG”), under the authority of the federal healthcare fraud and false claims statutes seeking documents related to the company’s brachytherapy business (the “Brachytherapy Matter”). On January 27, 2012, the company announced that it had reached a preliminary agreement with the civil and criminal divisions of the United States Attorney’s Office for the Northern District of Georgia to resolve claims with respect to the Brachytherapy Matter. In connection with this preliminary agreement, the company recorded a charge of approximately $51.0 million ($40.8 million after tax) in the fourth quarter of 2011. The ultimate settlement of this matter is subject to the negotiation and execution of definitive agreements, which will likely include civil settlement and non-prosecution agreements, and a corporate integrity

29

agreement with the OIG. If the definitive agreements are not finalized, the eventual costs related to this matter could be materially different than the previously recorded charge, and the company cannot give any assurances that this matter will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In December 2007, a U.S. District Court jury in Arizona found that certain of W.L. Gore & Associates Inc.’s (“Gore”) ePTFE vascular grafts and stent-grafts infringe the company’s patent number 6,436,135. The jury upheld the validity of the patent and awarded the company $185 million in past damages. The jury also found that Gore willfully infringed the patent. In a second phase of the trial, the District Court ruled that Gore failed to prove that the patent is unenforceable due to inequitable conduct. In March 2009, the District Court doubled the jury award to approximately $371 million for damages through June 2007. The District Court also awarded the company attorneys’ fees of $19 million and prejudgment interest of approximately $20 million. In addition, the District Court denied Gore’s remaining motions, including its motions for a new trial and to set aside the jury’s verdict. In July 2010, the District Court awarded the company approximately $109 million in additional damages for the period from July 2007 through March 2009. Gore has deposited or secured the foregoing amounts with the District Court. The District Court also assessed a royalty rate of between 12.5% and 20%, depending on the product, that will be used to calculate damages for Gore’s infringing sales from April 2009 through the expiration of the patent. Gore has made additional deposits with the District Court of approximately $401 million, representing Gore’s calculation of royalties for its infringing sales through June 2012. Gore appealed this matter to the Court of Appeals for the Federal Circuit (the “Court of Appeals”), which on February 10, 2012 affirmed the decision of the District Court. Gore filed a petition with the Court of Appeals for a rehearing of its appeal. On June 14, 2012, the Court of Appeals reaffirmed its February 10, 2012 decision, including the ongoing royalty rates as set by the District Court, with the exception of the issue of willfulness with respect to Gore’s infringement of Bard’s patent number 6,436,135, which was remanded to the District Court. On October 12, 2012, Gore filed a petition for a writ of certiorari to the U.S. Supreme Court requesting a review of the portion of the decision that the Court of Appeals reaffirmed. Since the company considers this matter a gain contingency, no amounts have been recorded. Even if the company is ultimately successful in this lawsuit, it cannot give any assurances that royalties for Gore’s future infringing sales will remain at or near historic levels.

The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under various federal laws including the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), commonly known as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state or foreign laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of the parties to the site contamination. The company’s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined. The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company’s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the company’s business and/or results of operations.

The company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.

Item 1A. Risk Factors

There have been no material changes to the risk factors disclosed in Part I, Item 1A. in Bard’s 2011 Annual Report on

Form 10-K.

30

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information with respect to the shares of the company’s common stock repurchased during the quarter ended September 30, 2012:

	Issuer Purchases of Equity Securities
Period	Total Number  of Shares Purchased(1)		Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Programs(2)		Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans  or Programs(2)
July 1 - July 31, 2012		803	$	107.44		—	$	588,296,656
August 1 - August 31, 2012		837,358		98.13		780,000		511,772,925
September 1 - September 30, 2012		1,257,667		101.94		1,255,861		383,747,818
Total		2,095,828	$	100.42		2,035,861	$	383,747,818

(1) The company repurchased 59,967 shares during the three month period ended September 30, 2012 that were not part of the publicly-announced share repurchase authorization. These shares were purchased from employees to satisfy tax withholding requirements on the vesting of restricted shares from equity-based awards.

(2) On June 9, 2010, the Board of Directors approved the repurchase of up to $500 million of common stock. The Board of Directors approved an additional repurchase of up to $500 million of common stock on June 13, 2012.

Item 5. Other Information

The company’s policy governing transactions in its securities by the company’s directors, executive officers and other specified employees permits such persons to adopt trading plans pursuant to Rule 10b5-1 of the Exchange Act. From time-to-time, the company’s executive officers have established trading plans relating to the company’s common stock under Rule 10b5-1, and the company anticipates additional trading plans may be established in the future. The company currently discloses details regarding individual trading plans on its website.

Item 6. Exhibits

Number	Description
12.1	Computation of Ratio of Earnings to Fixed Charges*
31.1	Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer*
31.2	Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer*
32.1	Section 1350 Certification of Chief Executive Officer (furnished herewith)
32.2	Section 1350 Certification of Chief Financial Officer (furnished herewith)
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

31

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	C. R. BARD, INC.
	(Registrant)
Date: October 24, 2012
	/s/    CHRISTOPHER S. HOLLAND
	Christopher S. Holland Senior Vice President and Chief Financial Officer
	/s/    FRANK LUPISELLA JR.
	Frank Lupisella Jr. Vice President and Controller

32

INDEX TO EXHIBITS

Number	Description
12.1	Computation of Ratio of Earnings to Fixed Charges
31.1	Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer
31.2	Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer
32.1	Section 1350 Certification of Chief Executive Officer (furnished herewith)
32.2	Section 1350 Certification of Chief Financial Officer (furnished herewith)
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

33

EX-12.1

EXHIBIT 12.1

C. R. BARD, INC. AND SUBSIDIARIES

Exhibit 12.1 - Computation of Ratio of Earnings to Fixed Charges

	Nine  Months Ended September  30, 2012			Years Ended December 31,
				2011			2010			2009			2008			2007
(dollars in millions)
Earnings from continuing operations before taxes	$	555.1		$	510.8		$	717.7		$	671.5		$	552.7		$	579.4
Add (Deduct):
Fixed charges		33.6			42.7			18.4			17.5			17.4			16.6
Undistributed earnings of equity investments		(6.2	)		(3.8	)		(3.6	)		(2.3	)		(1.9	)		(0.7	)
Earnings available for fixed charges	$	582.5		$	549.7		$	732.5		$	686.7		$	568.2		$	595.3
Fixed charges:
Interest, including amounts capitalized(1)	$	28.9		$	36.4		$	12.7		$	11.8		$	12.1		$	11.9
Proportion of rent expense deemed to represent interest factor		4.7			6.3			5.7			5.7			5.3			4.7
Fixed charges	$	33.6		$	42.7		$	18.4		$	17.5		$	17.4		$	16.6
Ratio of earnings to fixed charges		17.34			12.87			39.81			39.24			32.66			35.86

⁽¹⁾  Interest related to unrecognized tax benefits is included as income tax expense and not included in fixed charges.

EX-31.1

EXHIBIT 31.1

Certification of Chief Executive Officer

I, Timothy M. Ring, certify that:

1. I have reviewed this quarterly report on Form 10-Q of C. R. Bard, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 24, 2012

/s/ Timothy M. Ring

Timothy M. Ring

Chief Executive Officer

EX-31.2

EXHIBIT 31.2

Certification of Chief Financial Officer

I, Christopher S. Holland, certify that:

1. I have reviewed this quarterly report on Form 10-Q of C. R. Bard, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 24, 2012

/s/ Christopher S. Holland

Christopher S. Holland

Senior Vice President and Chief Financial Officer

EX-32.1

EXHIBIT 32.1

SECTION 1350 CERTIFICATIONS

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of C. R. Bard, Inc. on Form 10-Q for the period ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy M. Ring, Chairman and Chief Executive Officer of C. R. Bard, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of C. R. Bard, Inc.

/s/ Timothy M. Ring

Name: Timothy M. Ring

Date: October 24, 2012

EX-32.2

EXHIBIT 32.2

SECTION 1350 CERTIFICATIONS

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of C. R. Bard, Inc. on Form 10-Q for the period ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher S. Holland, Senior Vice President and Chief Financial Officer of C. R. Bard, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of C. R. Bard, Inc.

/s/ Christopher S. Holland

Name: Christopher S. Holland

Date: October 24, 2012

XML

Inventories (Detail) (USD $)	Sep. 30, 2012	Dec. 31, 2011
Inventory Disclosure [Line Items]
Finished goods	$ 205,100,000	$ 189,900,000
Work in process	20,100,000	21,300,000
Raw materials	110,700,000	108,000,000
Inventory, net, total	$ 335,900,000	$ 319,200,000

XML

Total Net Sales by Product Group Category (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Segment Reporting Information [Line Items]
Net sales	$ 722,900	$ 719,200	$ 2,195,500	$ 2,144,500
Vascular
Segment Reporting Information [Line Items]
Net sales	202,500	208,200	633,000	621,700
Urology
Segment Reporting Information [Line Items]
Net sales	188,100	182,200	562,000	544,400
Oncology
Segment Reporting Information [Line Items]
Net sales	203,900	198,900	601,900	578,100
Surgical Specialties
Segment Reporting Information [Line Items]
Net sales	107,700	107,600	333,800	333,400
Other Product Group
Segment Reporting Information [Line Items]
Net sales	$ 20,700	$ 22,300	$ 64,800	$ 66,900

XML

Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail) (USD $)	9 Months Ended
	Sep. 30, 2012		Sep. 30, 2011
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Change in Derivative Instruments Designated As Cash Flow Hedges	$ (1,400,000)
Other comprehensive income (loss) before income taxes, Change in Derivative Instruments Designated As Cash Flow Hedges	4,100,000		(6,700,000)
Income tax (provision) benefit related to other comprehensive income (loss) items, Change in Derivative Instruments Designated As Cash Flow Hedges	(2,000,000)	[1]	2,600,000	[1]
Ending balance, Change in Derivative Instruments Designated As Cash Flow Hedges	700,000		(4,100,000)
Beginning balance, Foreign Currency Translation Adjustment	41,100,000		29,000,000
Other comprehensive income (loss) before income taxes, Foreign Currency Translation Adjustment	(24,300,000)		41,900,000
Income tax (provision) benefit related to other comprehensive income (loss) items, Foreign Currency Translation Adjustment		[1]		[1]
Ending balance, Foreign Currency Translation Adjustment	16,800,000		70,900,000
Beginning balance, Benefit Plan Adjustments	(106,300,000)		(85,200,000)
Other comprehensive income (loss) before income taxes, benefit Plan Adjustments	8,000,000		6,000,000
Income tax (provision) benefit related to other comprehensive income (loss) items, Benefit Plan Adjustments	(2,800,000)	[1]	(2,100,000)	[1]
Ending balance, Benefit Plan Adjustments	(101,100,000)		(81,300,000)
Beginning balance, Accumulated Other Comprehensive (Loss) Income	(66,600,000)		(56,200,000)
Other comprehensive income (loss) before income taxes	(12,200,000)		41,200,000
Income tax (provision) benefit related to other comprehensive income (loss) items	(4,800,000)	[1]	500,000	[1]
Ending balance, Accumulated Other Comprehensive (Loss) Income	$ (83,600,000)		$ (14,500,000)

[1] Income taxes are not provided for foreign currency translation adjustments.

XML

Location and Amounts of Gains and Losses on Derivative Instruments Designated as Cash Flow Hedges (Parenthetical) (Detail) (USD $) In Millions, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Derivative Instruments, Gain (Loss) [Line Items]
Tax effect of amount reclassified from accumulated other comprehensive loss to income	$ 0.2	$ 0.7

XML

Segment Information (Tables)

9 Months Ended

Sep. 30, 2012

Net Sales Based on Location of External Customers by Geographic Region

Net sales based on the location of external customers by geographic region are:

	Quarter Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
(dollars in millions)
United States	$	483.4	$	486.5	$	1,469.6	$	1,453.5
Europe		115.6		124.2		369.3		380.3
Japan		41.6		36.1		122.2		103.9
Other		82.3		72.4		234.4		206.8
	$	722.9	$	719.2	$	2,195.5	$	2,144.5

Total Net Sales by Product Group Category

Total net sales by product group category are:

	Quarter Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
(dollars in millions)
Vascular	$	202.5	$	208.2	$	633.0	$	621.7
Urology		188.1		182.2		562.0		544.4
Oncology		203.9		198.9		601.9		578.1
Surgical Specialties		107.7		107.6		333.8		333.4
Other		20.7		22.3		64.8		66.9
	$	722.9	$	719.2	$	2,195.5	$	2,144.5

Segment Other Information

Other information is:

	Quarter Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
(dollars in millions)
Depreciation	$	13.2	$	12.2	$	40.2	$	39.0
Amortization	$	20.4	$	15.4	$	61.2	$	45.4

XML

Amounts Recognized for Share-Based Compensation (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total cost of share-based compensation plans	$ 11,500,000	$ 11,100,000	$ 39,000,000	$ 36,500,000
Amounts capitalized in inventory and fixed assets	(400,000)	(300,000)	(1,200,000)	(1,000,000)
Amounts recognized in income for amounts previously capitalized in inventory and fixed assets	400,000	300,000	1,200,000	1,200,000
Amounts charged against income	$ 11,500,000	$ 11,100,000	$ 39,000,000	$ 36,700,000

XML

Accounts Receivable, Net of Allowances (Detail) (USD $) In Millions, unless otherwise specified	Sep. 30, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	$ 56.6
Greater than 365 days past due	10.2
Spain
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	14.2
Greater than 365 days past due	1.3
Italy
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	26.8
Greater than 365 days past due	4.5
Greece
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	11.9
Greater than 365 days past due	3.8
Portugal
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	3.7	[1]
Greater than 365 days past due	$ 0.6	[1]

[1] Subsequent cash collections in the fourth quarter of 2012 were approximately $0.6 million, of which $0.2 million related to receivables greater than 365 days past due.

XML

Net Sales Based on Location of External Customers by Geographic Region (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Segment Reporting Information [Line Items]
Net sales	$ 722,900	$ 719,200	$ 2,195,500	$ 2,144,500
United States
Segment Reporting Information [Line Items]
Net sales	483,400	486,500	1,469,600	1,453,500
Europe
Segment Reporting Information [Line Items]
Net sales	115,600	124,200	369,300	380,300
Japan
Segment Reporting Information [Line Items]
Net sales	41,600	36,100	122,200	103,900
Other
Segment Reporting Information [Line Items]
Net sales	$ 82,300	$ 72,400	$ 234,400	$ 206,800

XML

Asset Impairments and Restructuring

9 Months Ended

Sep. 30, 2012

Asset Impairments and Restructuring

3. Asset Impairments and Restructuring

During the third quarter of 2012, the company recorded an asset impairment charge of $13.2 million ($8.0 million after tax). This charge relates to the write-down of certain core technologies associated with a non-strategic product in the company’s vascular product group. During the second quarter of 2012, the company recorded asset impairment charges of $9.0 million ($5.8 million after tax). The charges in the second quarter reflect impairments of assets not related to operations. These asset impairment charges were recorded to other (income) expense, net.

During the second half of 2011, the company initiated certain restructuring actions in order to improve its overall cost structure and enhance operational effectiveness. These actions included the realignment of certain sales functions in the United States. At September 30, 2012, the remaining liability related to these restructuring actions was $1.0 million, which reflects cash payments made in 2012 of $4.8 million and a reversal of $1.6 million of restructuring costs. The company expects activities under these restructuring actions to be substantially complete by the end of 2012.

XML

Components of Net Periodic Pension Cost (Detail) (Pension Plans, Defined Benefit, USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Pension Plans, Defined Benefit
Pension and Other Postretirement Benefits Disclosure [Line Items]
Service cost, net of employee contributions	$ 7.0	$ 6.8	$ 20.8	$ 20.3
Interest cost	4.9	4.8	14.6	14.2
Expected return on plan assets	(6.2)	(5.9)	(17.9)	(17.6)
Amortization	2.8	1.9	7.8	5.9
Net periodic pension cost	$ 8.5	$ 7.6	$ 25.3	$ 22.8

XML

Income Taxes - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Income Taxes [Line Items]
Company's effective tax rate	27.00%	29.00%	28.00%	42.00%
Liability for unrecognized tax benefits	$ 41.0		$ 41.0		$ 45.0
Liability for unrecognized tax benefits that would impact the effective tax rate, if recognized	34.7		34.7
Accrued interest on liability for unrecognized tax benefits	5.7		5.7		5.0
Expected decrease in unrecognized tax benefits within next 12 months	$ 2.5		$ 2.5

XML

Earnings Per Share Computation (Detail) (USD $) Share data in Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net income	$ 129,300,000	$ 130,100,000	$ 401,900,000	$ 214,200,000
Less: Income allocated to participating securities	2,400,000	2,300,000	7,700,000	4,000,000
Net income available to common shareholders	$ 126,900,000	$ 127,800,000	$ 394,200,000	$ 210,200,000
Weighted average common shares outstanding	83.4	86.6	83.8	86.0
Dilutive common share equivalents from share-based compensation plans	1.2	1.2	1.1	1.7
Weighted average common and common equivalent shares outstanding, assuming dilution	84.6	87.8	84.9	87.7

XML

Pension and Other Postretirement Benefit Plans - Additional Information (Detail) (Other Postretirement Benefit Plans, Defined Benefit, USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost	$ 0.2	$ 0.2	$ 0.5	$ 0.5

XML

Financial Instruments - Additional Information (Detail) (USD $)			9 Months Ended			9 Months Ended
	Sep. 30, 2012 Year	Dec. 31, 2011	Sep. 30, 2012 Line of Credit Facility	Sep. 30, 2012 Fair Value, Measurements, Recurring Fair Value, Inputs, Level 3	Dec. 31, 2011 Fair Value, Measurements, Recurring Fair Value, Inputs, Level 3	Sep. 30, 2012 Interest rate swap contract
Derivative [Line Items]
Notional value of forward currency and option contracts	$ 165,500,000	$ 205,200,000
Fixed-rate notes interest percentage						2.875%
Fixed-rate notes due date						2016
Notional value of interest rate swap contract						250,000,000
Fair value of contingent consideration				73,000,000	77,100,000
Fair value of commercial paper borrowings	381,500,000	304,500,000
Line of credit facility, borrowing capacity	600,000,000
Line of credit facility, years	5
Line of credit facility, expiration date			2016-10
Fair value of long-term debt	$ 1,000,000,000	$ 1,000,000,000

XML

Location and Fair Value of Derivative Instruments Segregated Between Designated and Not Designated Hedging Instruments (Detail) (USD $) In Millions, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Derivatives Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	$ 19.5	$ 17.9
Fair value of derivative liability	0.9	6.4
Derivatives Designated as Hedging Instruments | Forward currency contracts | Other Current Assets
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	1.3	1.5
Derivatives Designated as Hedging Instruments | Forward currency contracts | Other Assets
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	0.3
Derivatives Designated as Hedging Instruments | Forward currency contracts | Accrued Expenses
Derivatives, Fair Value [Line Items]
Fair value of derivative liability	0.8	6.4
Derivatives Designated as Hedging Instruments | Forward currency contracts | Other Long-Term Liabilities
Derivatives, Fair Value [Line Items]
Fair value of derivative liability	0.1
Derivatives Designated as Hedging Instruments | Option currency contracts | Other Current Assets
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	2.7	4.3
Derivatives Designated as Hedging Instruments | Option currency contracts | Other Assets
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	0.6
Derivatives Designated as Hedging Instruments | Interest rate swap contract | Other Assets
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	14.6	12.1
Derivatives Not Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Fair value of derivative assets		3.8
Derivatives Not Designated as Hedging Instruments | Forward currency contracts | Other Current Assets
Derivatives, Fair Value [Line Items]
Fair value of derivative assets		$ 3.8

XML

Acquisition

9 Months Ended

Sep. 30, 2012

Acquisition

2. Acquisition

On October 19, 2012, the company acquired Neomend, Inc. (“Neomend”), a privately-held company engaged in the development and commercialization of innovative surgical sealants. The purchase consideration consists of an up front cash payment of $140 million and contingent consideration of up to $25 million, based on the achievement of sales-based milestone payments through 2016. Neomend’s products expand Bard’s existing surgical specialties product portfolio to include the only product approved by the U.S. Food and Drug Administration for the treatment of intraoperative air leaks in connection with thoracic surgery. Neomend’s proprietary technology and pipeline provides the opportunity for future clinical indications across a variety of surgical specialty applications. The company has not yet completed the initial purchase accounting due to the timing of this acquisition.

XML

Location and Amounts of Gains and Losses on Derivative Instruments Designated as Cash Flow Hedges (Detail) (Cash flow hedges, USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012		Sep. 30, 2011
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized in Other Comprehensive Income	$ 0.1	$ (4.1)	$ 2.1		$ (4.1)
Gain/(Loss) Reclassified from Accumulated Other Comp. Loss into Income	0.2	(0.1)	0.9	[1]	0.8	[1]
Forward currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized in Other Comprehensive Income	1.2	(4.3)	3.3		(4.2)
Forward currency contracts | Costs Of Goods Sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Reclassified from Accumulated Other Comp. Loss into Income	(0.3)	(0.1)	(0.2)		0.8
Option currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized in Other Comprehensive Income	(1.1)	0.2	(1.2)		0.1
Option currency contracts | Costs Of Goods Sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Reclassified from Accumulated Other Comp. Loss into Income	$ 0.5		$ 1.1

[1] The tax effect of the amount reclassified from accumulated other comprehensive loss to income was $0.2 million and $0.7 million at September 30, 2012 and 2011, respectively.

XML

Contingencies - Additional Information (Detail) (USD $) In Millions, unless otherwise specified			1 Months Ended	3 Months Ended		9 Months Ended		9 Months Ended	12 Months Ended								9 Months Ended		1 Months Ended				1 Months Ended							1 Months Ended
	Sep. 30, 2012	Dec. 31, 2011	Jun. 30, 2007 Hernia Repair Products LegalMatter	Jun. 30, 2011 Hernia Repair Products	Dec. 31, 2011 Brachytherapy Matter	Sep. 30, 2012 WomenS Health Product Claims	Jul. 31, 2012 WomenS Health Product Claims	Sep. 30, 2012 Hernia Products Claims	Sep. 30, 2012 Hernia Products Claims	Dec. 31, 2011 Hernia Products Claims	Jun. 30, 2012 W. L. Gore	Jul. 31, 2010 W. L. Gore	Mar. 31, 2009 W. L. Gore	Dec. 31, 2007 W. L. Gore	Mar. 31, 2009 Attorney Fees	Mar. 31, 2009 Prejudgment Interest	Sep. 30, 2012 Other Legal Matter	Aug. 30, 2010 Superior Court of State of Rhode Island Hernia Repair Products	Oct. 18, 2012 Subsequent Event Hernia Repair Products Plaintiff	Oct. 18, 2012 Subsequent Event WomenS Health Product Claims Plaintiff	Oct. 18, 2012 Subsequent Event Filter Product Claims Plaintiff	Oct. 18, 2012 Subsequent Event United States LegalMatter	Oct. 18, 2012 Subsequent Event United States Hernia Repair Products LegalMatter	Oct. 18, 2012 Subsequent Event United States WomenS Health Product Claims LegalMatter	Oct. 18, 2012 Subsequent Event Canada Hernia Repair Products LegalMatter	Oct. 18, 2012 Subsequent Event Canada WomenS Health Product Claims LegalMatter	Oct. 18, 2012 Subsequent Event Federal Law Claims Hernia Repair Products LegalMatter	Oct. 18, 2012 Subsequent Event Federal Law Claims WomenS Health Product Claims LegalMatter	Oct. 18, 2012 Subsequent Event State Law Claims Hernia Repair Products LegalMatter	Oct. 18, 2012 Subsequent Event State Law Claims Filter Product Claims LegalMatter	Oct. 18, 2012 Subsequent Event Superior Court of State of Rhode Island Hernia Repair Products Plaintiff	Oct. 18, 2012 Subsequent Event Superior Court of State of Rhode Island State Law Claims Hernia Repair Products LegalMatter
Loss Contingencies [Line Items]
Number of lawsuits																						1					1,505	1,195	755			730
Number of individual plaintiffs																			2,400	1,580	60										830
Number of putative class actions																							2	4	3	1				3
Number of previously filed class action lawsuits																						10
Number of Multidistrict Litigations			1
U. S. District Court award for plaintiff's damages							$ 3.6											$ 1.5
Product Claims, charges incurred before taxes				184.3
Product Claims, charges incurred after tax				180.6
Receivable insurance coverage disputed								25.0									30.0
Insurance coverage disputed						50
Legal settlement costs, gross					51.0
Legal settlement costs, net of tax					40.8
U. S. District Court award for damages												109	371	185	19	20
Court-assessed royalty rate, lower limit												12.50%
Court-assessed royalty rate, upper limit												20.00%
Escrow deposit representing an estimation of liability											401
Accruals for product liability and other legal matters	168.8	287.3
Payments to qualified settlement fund								6.2	155.4
Cumulative payments from qualified settlement fund to qualified claimants									127.9
Payments to qualified claimants from qualified settlement funds								125.8
Cumulative other payments to qualified claimants from qualified settlement funds									8.0
Other payments to qualified claimants from qualified settlement funds								5.4
Receivables from insurance companies								$ 55.7	$ 55.7	$ 51.0

XML

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Net sales	$ 722,900	$ 719,200	$ 2,195,500	$ 2,144,500
Costs and expenses:
Cost of goods sold	272,600	274,900	837,700	815,200
Marketing, selling and administrative expense	196,600	189,300	604,300	580,400
Research and development expense	52,200	46,900	150,500	141,800
Interest expense	9,700	9,000	28,900	27,100
Other (income) expense, net	13,600	17,000	19,000	211,200
Total costs and expenses	544,700	537,100	1,640,400	1,775,700
Income from operations before income taxes	178,200	182,100	555,100	368,800
Income tax provision	48,900	52,000	153,200	154,600
Net income	$ 129,300	$ 130,100	$ 401,900	$ 214,200
Basic earnings per share available to common shareholders	$ 1.52	$ 1.48	$ 4.70	$ 2.44
Diluted earnings per share available to common shareholders	$ 1.50	$ 1.46	$ 4.64	$ 2.40

XML

Shareholders' Investment - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	9 Months Ended
	Sep. 30, 2012 Program
Shareholders Equity [Line Items]
Number of shares of common stock purchased	3.8
Purchase of common stock	$ 367.2
Share repurchase program, authorized amount	$ 500
Number of share repurchase programs	2

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net income	$ 401,900	$ 214,200
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	101,400	84,400
Asset impairments	22,200
Restructuring, net of payments	(1,600)	7,800
Impairment charge for foreign government bonds		7,000
Legal settlements and commitments, net of payments		184,800
Acquired in-process research and development	2,000	3,500
Deferred income taxes	12,600	(12,200)
Share-based compensation	39,000	36,700
Inventory reserves and provision for doubtful accounts	15,000	10,900
Other items	(5,800)	(2,100)
Changes in assets and liabilities:
Accounts receivable	31,600	(14,300)
Inventories	(34,000)	(19,800)
Current liabilities	(153,900)	2,000
Taxes	(2,500)	36,600
Other, net	(700)	9,900
Net cash provided by operating activities	427,200	549,400
Cash flows from investing activities:
Capital expenditures	(55,500)	(49,900)
Change in restricted cash	119,600	(200,300)
Payments made for intangibles	(14,100)	(16,600)
Proceeds from sale of financial instruments	10,000
Net cash provided by (used in) investing activities	60,000	(266,800)
Cash flows from financing activities:
Change in short-term borrowings, net	77,000	(80,500)
Proceeds from exercises under share-based compensation plans, net	70,200	96,100
Excess tax benefit relating to share-based compensation plans	10,300	23,800
Purchases of common stock	(372,500)	(155,100)
Dividends paid	(49,900)	(48,200)
Other	(4,900)	(2,200)
Net cash used in financing activities	(269,800)	(166,100)
Effect of exchange rate changes on cash and cash equivalents	(4,700)	9,100
Increase in cash and cash equivalents during the period	212,700	125,600
Balance at January 1	596,400	641,400
Balance at September 30	809,100	767,000
Cash paid for:
Interest	31,600	20,100
Income taxes	132,800	106,400
Non-cash transactions:
Receipt of foreign government bonds		16,800
Purchase of common stock not settled	$ 9,100	$ 19,100

XML

Location and Amounts of Gains and Losses on Derivative Instruments Not Designated as Hedging Instruments (Detail) (Forward currency contracts, Other (income) expense, net, USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2011		Sep. 30, 2012		Sep. 30, 2011
Forward currency contracts | Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized in Earnings	$ (5.1)	[1]	$ 3.0	[1]	$ (0.5)	[1]

[1] These derivative contracts mitigate changes in the value of remeasured foreign currency denominated intercompany loans attributable to changes in foreign currency exchange rates.

XML

Share-Based Compensation Plans (Tables)

9 Months Ended

Sep. 30, 2012

Amounts Recognized for Share-Based Compensation

Amounts recognized for share-based compensation are as follows:

	Quarter Ended September  30,						Nine Months  Ended September 30,
	2012			2011			2012			2011
(dollars in millions)
Total cost of share-based compensation plans	$	11.5		$	11.1		$	39.0		$	36.5
Amounts capitalized in inventory and fixed assets		(0.4	)		(0.3	)		(1.2	)		(1.0	)
Amounts recognized in income for amounts previously capitalized in inventory and fixed assets		0.4			0.3			1.2			1.2
Amounts charged against income	$	11.5		$	11.1		$	39.0		$	36.7

XML

Financial Instrument Assets and (Liabilities) Measured at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring, USD $) In Millions, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Foreign government bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial instrument assets and (liabilities) measured at fair value		$ 3.6
Forward currency contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial instrument assets and (liabilities) measured at fair value	0.7	(1.1)
Option currency contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial instrument assets and (liabilities) measured at fair value	3.3	4.3
Interest rate swap contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial instrument assets and (liabilities) measured at fair value	$ 14.6	$ 12.1

XML

Shareholders' Investment (Tables)

9 Months Ended

Sep. 30, 2012

Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss)

The accumulated balances related to each component of other comprehensive income (loss) are as follows:

	Change in Derivative Instruments Designated As Cash Flow  Hedges			Foreign  Currency Translation Adjustment			Benefit  Plan Adjustments			Accumulated Other Comprehensive (Loss) Income
(dollars in millions)
Balance at December 31, 2011	$	(1.4	)	$	41.1		$	(106.3	)	$	(66.6	)
Other comprehensive income (loss) before income taxes		4.1			(24.3	)		8.0			(12.2	)
Income tax (provision) benefit related to other comprehensive income (loss) items (A)		(2.0	)		—			(2.8	)		(4.8	)
Balance at September 30, 2012	$	0.7		$	16.8		$	(101.1	)	$	(83.6	)
Balance at December 31, 2010	$	—		$	29.0		$	(85.2	)	$	(56.2	)
Other comprehensive income (loss) before income taxes		(6.7	)		41.9			6.0			41.2
Income tax (provision) benefit related to other comprehensive income (loss) items (A)		2.6			—			(2.1	)		0.5
Balance at September 30, 2011	$	(4.1	)	$	70.9		$	(81.3	)	$	(14.5	)

^(A)  Income taxes are not provided for foreign currency translation adjustments.

XML

Basis of Presentation

9 Months Ended

Sep. 30, 2012

Basis of Presentation

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of C. R. Bard, Inc. and its subsidiaries (the “company” or “Bard”) should be read in conjunction with the audited consolidated financial statements and notes thereto included in Bard’s 2011 Annual Report on Form 10-K. These financial statements have been prepared on a basis that is substantially consistent with the accounting principles applied in the financial statements in Bard’s 2011 Annual Report on Form 10-K. The preparation of these financial statements requires the company to make estimates and judgments that affect reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities at the date of the financial statements. These financial statements include all normal and recurring adjustments necessary for a fair presentation. The accounts of most foreign subsidiaries are consolidated as of and for the quarter and nine months ended August 31, 2012 and August 31, 2011 and as of November 30, 2011. No events occurred related to these foreign subsidiaries during the months of September 2012, September 2011 or December 2011 that materially affected the financial position or results of operations of the company. The results for the interim periods presented are not necessarily indicative of the results expected for the year.

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Net income	$ 129,300	$ 130,100	$ 401,900	$ 214,200
Other comprehensive income (loss), net of tax
Change in derivative instruments designated as cash flow hedges	100	(4,100)	2,100	(4,100)
Foreign currency translation adjustments	14,900	(9,400)	(24,300)	41,900
Benefit plan adjustments	1,800	1,300	5,200	3,900
Available-for-sale securities		2,100
Other comprehensive income (loss)	16,800	(10,100)	(17,000)	41,700
Comprehensive income	$ 146,100	$ 120,000	$ 384,900	$ 255,900

XML

Shareholders' Investment

9 Months Ended

Sep. 30, 2012

Shareholders' Investment

11. Shareholders’ Investment

The company repurchased approximately 3.8 million shares of common stock for $367.2 million during the nine months ended September 30, 2012 under two previously announced $500 million share repurchase programs.

Other Comprehensive Income (Loss)

On January 1, 2012, the company adopted Financial Accounting Standards Board amended guidance, with the exception of an amendment providing for a deferral of a certain provision, on the presentation of other comprehensive income and its components in the consolidated condensed financial statements. The company has elected to present net income and comprehensive income as two separate but consecutive statements. This guidance was applied retrospectively, as required.

The accumulated balances related to each component of other comprehensive income (loss) are as follows:

	Change in Derivative Instruments Designated As Cash Flow  Hedges			Foreign  Currency Translation Adjustment			Benefit  Plan Adjustments			Accumulated Other Comprehensive (Loss) Income
(dollars in millions)
Balance at December 31, 2011	$	(1.4	)	$	41.1		$	(106.3	)	$	(66.6	)
Other comprehensive income (loss) before income taxes		4.1			(24.3	)		8.0			(12.2	)
Income tax (provision) benefit related to other comprehensive income (loss) items (A)		(2.0	)		—			(2.8	)		(4.8	)
Balance at September 30, 2012	$	0.7		$	16.8		$	(101.1	)	$	(83.6	)
Balance at December 31, 2010	$	—		$	29.0		$	(85.2	)	$	(56.2	)
Other comprehensive income (loss) before income taxes		(6.7	)		41.9			6.0			41.2
Income tax (provision) benefit related to other comprehensive income (loss) items (A)		2.6			—			(2.1	)		0.5
Balance at September 30, 2011	$	(4.1	)	$	70.9		$	(81.3	)	$	(14.5	)

^(A)  Income taxes are not provided for foreign currency translation adjustments.

XML

Document and Entity Information	9 Months Ended
	Sep. 30, 2012
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Trading Symbol	BCR
Entity Registrant Name	BARD C R INC /NJ/
Entity Central Index Key	0000009892
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	82,311,961

XML

Segment Information

9 Months Ended

Sep. 30, 2012

Segment Information

12. Segment Information

The company’s management considers its business to be a single segment entity—the manufacture and sale of medical devices. The company’s products generally share similar distribution channels and customers. The company designs, develops, manufactures, packages, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells a broad range of products to hospitals, individual healthcare professionals, extended care health facilities and alternate site facilities on a global basis. In general, the company’s products are intended to be used once and then discarded or either temporarily or permanently implanted. The company’s chief operating decision makers evaluate their various global product portfolios on a net sales basis and generally evaluate profitability and associated investment on an enterprise-wide basis due to shared geographic infrastructures.

Net sales based on the location of external customers by geographic region are:

	Quarter Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
(dollars in millions)
United States	$	483.4	$	486.5	$	1,469.6	$	1,453.5
Europe		115.6		124.2		369.3		380.3
Japan		41.6		36.1		122.2		103.9
Other		82.3		72.4		234.4		206.8
	$	722.9	$	719.2	$	2,195.5	$	2,144.5

Total net sales by product group category are:

	Quarter Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
(dollars in millions)
Vascular	$	202.5	$	208.2	$	633.0	$	621.7
Urology		188.1		182.2		562.0		544.4
Oncology		203.9		198.9		601.9		578.1
Surgical Specialties		107.7		107.6		333.8		333.4
Other		20.7		22.3		64.8		66.9
	$	722.9	$	719.2	$	2,195.5	$	2,144.5

Other information is:

	Quarter Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
(dollars in millions)
Depreciation	$	13.2	$	12.2	$	40.2	$	39.0
Amortization	$	20.4	$	15.4	$	61.2	$	45.4

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Current assets
Cash and cash equivalents	$ 809,100	$ 596,400
Restricted cash	27,500	147,100
Accounts receivable, less allowances of $11,700 and $10,000, respectively	475,000	488,900
Inventories	335,900	319,200
Short-term deferred tax assets	58,200	61,200
Other current assets	79,700	73,100
Total current assets	1,785,400	1,685,900
Property, plant and equipment, at cost	641,800	627,500
Less accumulated depreciation and amortization	287,500	272,100
Net property, plant and equipment	354,300	355,400
Goodwill	905,800	916,700
Core technologies, net	444,500	498,700
Other intangible assets, net	343,800	352,600
Deferred tax assets	8,700	19,700
Other assets	90,000	102,100
Total assets	3,932,500	3,931,100
Current liabilities
Short-term borrowings	381,500	304,500
Accounts payable	64,800	86,400
Accrued expenses	224,100	380,400
Accrued compensation and benefits	104,700	124,400
Income taxes payable	9,600	8,400
Total current liabilities	784,700	904,100
Long-term debt	911,400	908,700
Other long-term liabilities	322,000	319,600
Deferred income taxes	16,600	16,500
Commitments and contingencies
Shareholders' investment:
Preferred stock, $1 par value, authorized 5,000,000 shares; none issued
Common stock, $0.25 par value, authorized 600,000,000 shares; issued and outstanding 82,311,961 shares at September 30, 2012 and 84,543,338 shares at December 31, 2011	20,600	21,200
Capital in excess of par value	1,480,700	1,349,800
Retained earnings	480,100	477,800
Accumulated other comprehensive loss	(83,600)	(66,600)
Total shareholders' investment	1,897,800	1,782,200
Total liabilities and shareholders' investment	$ 3,932,500	$ 3,931,100

XML

Financial Instruments

9 Months Ended

Sep. 30, 2012

Financial Instruments

6. Financial Instruments

Foreign Exchange Derivative Instruments

The company enters into readily marketable forward and option contracts with financial institutions to help reduce its exposure to foreign currency exchange rate fluctuations. These contracts limit volatility because gains and losses associated with foreign currency exchange rate movements are generally offset by movements in the underlying hedged item. The notional value of the company’s forward currency and option currency contracts was $165.5 million and $205.2 million at September 30, 2012 and December 31, 2011, respectively. For further discussion regarding the company’s use of derivative instruments, see Note 1 of the consolidated financial statements in Bard’s 2011 Annual Report on Form 10-K.

Interest Rate Derivative Instrument

The company’s outstanding interest rate swap contract effectively converts its 2.875% fixed-rate notes due 2016 to a floating-rate instrument. The notional value of the company’s interest rate swap contract is $250.0 million.

The location and fair value of derivative instruments segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:

	Balance Sheet Location	Fair Value of Derivatives
Derivatives Designated as Hedging Instruments		September 30, 2012		December 31, 2011
(dollars in millions)
Forward currency contracts	Other current assets	$	1.3	$	1.5
Option currency contracts	Other current assets		2.7		4.3
Forward currency contracts	Other assets		0.3		—
Option currency contracts	Other assets		0.6		—
Interest rate swap contract	Other assets		14.6		12.1
		$	19.5	$	17.9
Forward currency contracts	Accrued expenses	$	0.8	$	6.4
Forward currency contracts	Other long-term liabilities		0.1		—
		$	0.9	$	6.4
Derivatives Not Designated as Hedging Instruments
(dollars in millions)
Forward currency contracts	Other current assets	$	—	$	3.8
		$	—	$	3.8

The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders’ investment are as follows:

	Gain/(Loss) Recognized  in Other Comprehensive Income						Location of Gain/(Loss) Reclassified from Accumulated Other Comp. Loss to Income	Gain/(Loss)  Reclassified from Accumulated Other Comp. Loss into Income
	Quarter Ended September 30,							Quarter Ended September  30,
	2012			2011				2012			2011
(dollars in millions)
Forward currency contracts	$	1.2		$	(4.3	)	Costs of goods sold	$	(0.3	)	$	(0.1	)
Option currency contracts		(1.1	)		0.2		Costs of goods sold		0.5			—
	$	0.1		$	(4.1	)		$	0.2		$	(0.1	)
	Gain/(Loss) Recognized in  Other Comprehensive Income						Location of Gain/(Loss) Reclassified from Accumulated Other Comp. Loss to Income	Gain/(Loss) Reclassified from Accumulated Other Comp. Loss into Income
	Nine Months Ended September 30,							Nine Months Ended September 30,
	2012			2011				2012			2011
(dollars in millions)
Forward currency contracts	$	3.3		$	(4.2	)	Costs of goods sold	$	(0.2	)	$	0.8
Option currency contracts		(1.2	)		0.1		Costs of goods sold		1.1			—
	$	2.1		$	(4.1	)		$	0.9	(A)	$	0.8	(A)

^(A)  The tax effect of the amount reclassified from accumulated other comprehensive loss to income was $0.2 million and $0.7 million at September 30, 2012 and 2011, respectively.

The location and amounts of gains and losses on the derivative instrument designated as a fair value hedge are as follows:

	Income  Statement Location	Gain Recognized on Swap								Loss Recognized on Long-Term Debt
		Quarter Ended September  30,				Nine Months  Ended September 30,				Quarter Ended September  30,						Nine Months  Ended September 30,
		2012		2011		2012		2011		2012			2011			2012			2011
(dollars in millions)
Interest rate swap contract	Interest expense	$	1.0	$	7.7	$	2.5	$	11.7	$	(1.0	)	$	(7.7	)	$	(2.5	)	$	(11.7	)

The location and amounts of gains and losses on derivative instruments not designated as hedging instruments are as follows:

	Income  Statement Location	Gain/(Loss) Recognized in Earnings
		Quarter Ended September  30,					Nine Months  Ended September 30,
		2012		2011			2012		2011
(dollars in millions)
Forward currency contracts(A)	Other (income) expense, net	$	—	$	(5.1	)	$	3.0	$	(0.5	)

^(A) These derivative contracts mitigate changes in the value of remeasured foreign currency denominated intercompany loans attributable to changes in foreign currency exchange rates.

Financial Instruments Measured at Fair Value on a Recurring Basis

Fair value is defined as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy range from Level 1 having observable inputs to Level 3 having unobservable inputs.

The following table summarizes certain financial instrument assets and (liabilities) measured at fair value on a recurring basis:

	September 30, 2012		December 31, 2011
(dollars in millions)
Foreign government bonds and notes	$	—	$	3.6
Forward currency contracts		0.7		(1.1	)
Option currency contracts		3.3		4.3
Interest rate swap contract		14.6		12.1

The fair values were measured using significant other observable inputs and valued by reference to similar financial instruments, adjusted for restrictions and other terms specific to each instrument. These financial instruments are categorized as Level 2 under the fair value hierarchy.

The fair value of the liability for contingent consideration related to prior acquisitions was $73.0 million and $77.1 million at September 30, 2012 and December 31, 2011, respectively. The fair value was measured using significant unobservable inputs and is categorized as Level 3 under the fair value hierarchy.

Financial Instruments not Measured at Fair Value

The fair value of commercial paper borrowings of $381.5 million and $304.5 million at September 30, 2012 and December 31, 2011, respectively, approximated carrying value. The company maintains a $600 million five-year committed syndicated bank credit facility that expires in October 2016. The credit facility supports the company’s commercial paper program and can be used for general corporate purposes. The facility includes pricing based on the company’s long-term credit rating and includes a financial covenant that limits the amount of total debt to total capitalization.

The estimated fair value of long-term debt including the effect of the related interest rate swap contract was approximately $1.0 billion at both periods ended September 30, 2012 and December 31, 2011. The fair value was estimated using dealer quotes for similarly-rated debt instruments over the remaining contractual term of the company’s obligation. Long-term debt is categorized as Level 2 under the fair value hierarchy.

Concentration Risk

Accounts receivable balances include sales to government-supported healthcare systems outside the United States. The company continues to monitor sovereign debt issues and economic conditions in Europe and evaluates accounts receivable in certain countries for potential collection risks. Deteriorating economic conditions and other factors in certain countries in Europe have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these accounts receivable and may require the company to re-evaluate the collectability of these receivables in future periods. The company has experienced significant delays in the collection of accounts receivable associated with the national healthcare systems in Spain, Italy, Greece and Portugal. At September 30, 2012, the company’s accounts receivable, net of allowances, from the national healthcare systems in these countries and amounts past due greater than 365 days are as follows:

	Accounts receivable, net		Greater than 365 days past due
(dollars in millions)
Spain	$	14.2	$	1.3
Italy		26.8		4.5
Greece		11.9		3.8
Portugal (A)		3.7		0.6
	$	56.6	$	10.2

^(A)  Subsequent cash collections in the fourth quarter of 2012 were approximately $0.6 million, of which $0.2 million related to receivables greater than 365 days past due.

In March 2012, the Greek government approved a private sector bond exchange program for holders of Greek public debt, including those bonds held by the company. As a result, the company’s bonds were exchanged for a combination of new Greek government bonds and certain other notes. These bonds and notes were classified as available-for-sale securities and were reported at fair value. In July 2012, the company sold these bonds and notes.

XML

Income Taxes

9 Months Ended

Sep. 30, 2012

Income Taxes

5. Income Taxes

The effective tax rate for the quarter ended September 30, 2012 was approximately 27% compared to approximately 29% for the same period in 2011. The effective tax rate for the nine months ended September 30, 2012 was approximately 28% compared to approximately 42% for the same period in 2011. The higher effective tax rate for the prior nine month period reflected the discrete tax effect of a charge for legal settlements, primarily related to Hernia Product Claims (see Note 8 of the notes to condensed consolidated financial statements), which were incurred in a low tax jurisdiction. At September 30, 2012, the total amount of liability for unrecognized tax benefits related to federal, state and foreign taxes was $41.0 million (of which $34.7 million would impact the effective tax rate, if recognized) plus $5.7 million of accrued interest. At December 31, 2011, the liability for unrecognized tax benefits was $45.0 million plus $5.0 million of accrued interest. Depending upon the result of open tax examinations and/or the expiration of applicable statutes of limitation, the company believes it is reasonably possible that the total amount of unrecognized tax benefits may decrease by up to $2.5 million within the next 12 months.

XML

Pension and Other Postretirement Benefit Plans (Tables)

9 Months Ended

Sep. 30, 2012

Components of Net Periodic Pension Cost

The components of net periodic pension cost are as follows:

	Quarter Ended September  30,						Nine Months  Ended September 30,
	2012			2011			2012			2011
(dollars in millions)
Service cost, net of employee contributions	$	7.0		$	6.8		$	20.8		$	20.3
Interest cost		4.9			4.8			14.6			14.2
Expected return on plan assets		(6.2	)		(5.9	)		(17.9	)		(17.6	)
Amortization		2.8			1.9			7.8			5.9
Net periodic pension cost	$	8.5		$	7.6		$	25.3		$	22.8

XML

Earnings per Common Share (Tables)

9 Months Ended

Sep. 30, 2012

Earnings Per Share Computation

Earnings per share (“EPS”) is computed under the two-class method using the following common share information:

	Quarter Ended September  30,				Nine Months Ended September 30,
	2012		2011		2012		2011
(dollars and shares in millions)
EPS Numerator:
Net income	$	129.3	$	130.1	$	401.9	$	214.2
Less: Income allocated to participating securities		2.4		2.3		7.7		4.0
Net income available to common shareholders	$	126.9	$	127.8	$	394.2	$	210.2
EPS Denominator:
Weighted average common shares outstanding		83.4		86.6		83.8		86.0
Dilutive common share equivalents from share-based compensation plans		1.2		1.2		1.1		1.7
Weighted average common and common equivalent shares outstanding, assuming dilution		84.6		87.8		84.9		87.7

XML

Share-Based Compensation Plans

9 Months Ended

Sep. 30, 2012

Share-Based Compensation Plans

9. Share-Based Compensation Plans

The company may grant a variety of share-based payments under the 2012 Long Term Incentive Plan of C. R. Bard, Inc., as amended and restated (formerly the 2003 Long Term Incentive Plan of C. R. Bard, Inc., as amended and restated) (the “Plan”) and the 2005 Directors’ Stock Award Plan of C. R. Bard, Inc., as amended and restated (the “Directors’ Plan”) to certain directors, officers and employees. At the company’s Annual Meeting of Shareholders on April 18, 2012, the shareholders authorized an additional 2,750,000 shares for issuance under the Plan. In addition, shareholders approved an amendment modifying the structure of the Plan so that each stock option granted will reduce the number of total shares available under the Plan by one share, and each full-value share-based award will reduce the number of total shares available under the Plan by 2.87 shares. The total number of remaining shares at September 30, 2012 that may be issued under the Plan was 5,904,609 and under the Directors’ Plan was 49,099. Awards under the Plan may be in the form of stock options, stock appreciation rights, limited stock appreciation rights, restricted stock, unrestricted stock and other stock-based awards. Awards under the Directors’ Plan may be in the form of stock awards, stock options or stock appreciation rights. The company has two employee stock purchase programs. On April 18, 2012, the shareholders authorized an additional 750,000 shares for issuance under the Employee Stock Purchase Plan of C. R. Bard, Inc., as Amended and Restated (formerly the 1998 Employee Stock Purchase Plan of C. R. Bard, Inc., as Amended and Restated).

Amounts recognized for share-based compensation are as follows:

	Quarter Ended September  30,						Nine Months  Ended September 30,
	2012			2011			2012			2011
(dollars in millions)
Total cost of share-based compensation plans	$	11.5		$	11.1		$	39.0		$	36.5
Amounts capitalized in inventory and fixed assets		(0.4	)		(0.3	)		(1.2	)		(1.0	)
Amounts recognized in income for amounts previously capitalized in inventory and fixed assets		0.4			0.3			1.2			1.2
Amounts charged against income	$	11.5		$	11.1		$	39.0		$	36.7

In the first quarter of 2012, the company granted performance restricted stock units to certain officers. These units have requisite service periods of three years and have no dividend rights. The actual payout of these units varies based on the company’s performance over the three-year period against pre-established targets, including a performance condition based on average earnings per share growth over the period and a market condition modifier based on total shareholder return (“TSR”) compared to an industry peer group. The actual payout under these awards may vary from zero to 200% of an officer’s target payout. Compensation cost initially recognized assumes that the target payout level will be achieved and is adjusted for subsequent changes in the expected outcome of the performance-related condition. The fair value of these units is based on the market price of the company’s stock on the date of grant and uses a Monte Carlo simulation model for the TSR component. The fair value of the TSR component was estimated based on the following assumptions: risk-free interest rate of 0.41%; dividend yield of 0.85%; and expected life of 2.83 years.

Anticipated purchases under the Management Stock Purchase Program (the “MSPP”) were approximately 0.2 million shares in each year presented and the fair value per share related to these purchases was $38.33 and $38.25, respectively. The fair values of the 2012 and 2011 annual MSPP purchases were estimated in July 2012 and July 2011, respectively, using the Black-Scholes model based on the following assumptions: risk-free interest rate of 0.16% and 0.12%, respectively; expected volatility of 20% and 16%, respectively; dividend yield of 0.9% and 0.8%, respectively; and expected life of 0.6 years for both valuations.

As of September 30, 2012, there were $78.3 million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately two years. The company has sufficient shares to satisfy expected share-based payment arrangements in 2012.

XML

Inventories

9 Months Ended

Sep. 30, 2012

Inventories

7. Inventories

Inventories consisted of:

	September 30, 2012		December 31, 2011
(dollars in millions)
Finished goods	$	205.1	$	189.9
Work in process		20.1		21.3
Raw materials		110.7		108.0
	$	335.9	$	319.2

XML

Contingencies

9 Months Ended

Sep. 30, 2012

Contingencies

8. Contingencies

General

In the ordinary course of business, the company is subject to various legal proceedings and claims, including, for example, product liability matters, environmental matters, employment disputes, disputes on agreements and other commercial disputes. In addition, the company operates in an industry susceptible to significant patent legal claims. The company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and reasonably estimable. Legal costs associated with these matters are expensed as incurred. At any given time, in the ordinary course of business, the company is involved as either a plaintiff or defendant in a number of patent infringement actions. If a third party’s patent infringement claim were to be determined against the company, the company might be required to make significant royalty or other payments or might be subject to an injunction or other limitation on its ability to manufacture or distribute one or more products. If a patent owned by or licensed to the company was determined to be invalid or unenforceable, the company might be required to reduce the value of certain intangible assets on the company’s balance sheet and to record a corresponding charge, which could be significant in amount. The company believes that any of these proceedings and claims could have a material adverse effect on its business, results of operations, financial condition and/or liquidity.

Product Liability Matters

As of October 18, 2012, approximately 1,505 federal and 755 state lawsuits involving individual claims by approximately 2,400 plaintiffs, as well as two putative class actions in the United States and three putative class actions in various Canadian provinces, have been filed or asserted against the company with respect to its Composix^® Kugel^® and certain other hernia repair implant products (collectively, the “Hernia Product Claims”). One of the U.S. class action lawsuits consolidates ten previously-filed U.S. class action lawsuits. The putative class actions, none of which has been certified, seek (i) medical monitoring, (ii) compensatory damages, (iii) punitive damages, (iv) a judicial finding of defect and causation and/or (v) attorneys’ fees. Approximately 730 of the state lawsuits, involving individual claims by approximately 830 plaintiffs, are pending in the Superior Court of the State of Rhode Island, with the remainder in various other jurisdictions. The Hernia Product Claims also generally seek damages for personal injury resulting from use of the products. The company voluntarily recalled certain sizes and lots of the Composix^® Kugel^® products beginning in December 2005.

In June 2007, the Judicial Panel on Multidistrict Litigation (“JPML”) transferred Composix^® Kugel^® lawsuits pending in federal courts nationwide into one Multidistrict Litigation (“MDL”) for coordinated pre-trial proceedings in the United States District Court for the District of Rhode Island. The MDL court subsequently determined to include other hernia repair products of the company in the MDL proceeding. The first MDL trial was completed in April 2010 and resulted in a judgment for the company based on the jury’s finding that the company was not liable for the plaintiff’s damages. The second MDL trial was completed in August 2010 and resulted in a judgment for the plaintiff of $1.5 million. On June 30, 2011, the company announced that it had reached agreements in principle with various plaintiffs’ law firms to settle the majority of its existing Hernia Product Claims. Each agreement is subject to certain conditions, including requirements for participation in the proposed settlements by a certain minimum number of plaintiffs. In addition, the company continues to engage in discussions with other plaintiffs’ law firms regarding potential resolution of unsettled Hernia Product Claims, and intends to vigorously defend Hernia Product Claims that do not settle, including through litigation. Additional trials are scheduled in the first quarter of 2013. Based on these events, the company recorded to other (income) expense, net, a charge of $184.3 million ($180.6 million after tax) in the second quarter of 2011, which recognized the estimated costs of settling all Hernia Product Claims, including asserted and unasserted claims, and costs to administer the settlements. The charge excludes any costs associated with pending putative class action lawsuits. The company cannot give any assurances that the actual costs incurred with respect to the Hernia Product Claims will not exceed the amount of the charge together with amounts previously accrued. The company cannot give any assurances that the resolution of the Hernia Product Claims that have not settled, including asserted and unasserted claims and the putative class action lawsuits, will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

As of October 18, 2012, product liability lawsuits involving individual claims by approximately 1,580 plaintiffs have been filed or asserted against the company in various federal and state jurisdictions alleging personal injuries associated with the use of certain of the company’s surgical continence products for women, principally its Avaulta^® line of products. In addition, four putative class actions in the United States and one putative class action in Canada have been filed against the company (all lawsuits, collectively, the “Women’s Health Product Claims”). The Women’s Health Product Claims generally seek damages for personal injury resulting from use of the products. The putative class actions, none of which has been certified, seek (i) medical monitoring, (ii) compensatory damages, (iii) punitive damages, (iv) a judicial finding of defect and causation and/or (v) attorneys’ fees. With respect to certain of these claims, the company believes that one of its suppliers has an obligation to defend and indemnify the company. In October 2010, the JPML transferred the Women’s Health Product Claims involving solely Avaulta^® products pending in federal courts nationwide into an MDL for coordinated pre-trial proceedings in the United States District Court for the Southern District of West Virginia. In February 2012, the JPML expanded the scope of and renamed the MDL pending in the United States District Court for the Southern District of West Virginia to include lawsuits involving all women’s surgical continence products that are manufactured or distributed by the company. In total, approximately 1,195 of the Women’s Health Product Claims are pending in federal courts and have been or will be transferred to the MDL in West Virginia, with the remainder of the Women’s Health Product Claims in other jurisdictions. Trial dates have been scheduled in the MDL beginning in March 2013. The first trial in one of these other jurisdictions was completed in July 2012 and resulted in a judgment against the company of approximately $3.6 million. The company has appealed this decision. The company does not believe that this verdict is representative of the potential outcomes of other Women’s Health Product Claims. While the company intends to vigorously defend the Women’s Health Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

As of October 18, 2012, product liability lawsuits involving individual claims by approximately 60 plaintiffs have been filed or asserted against the company in various federal and state jurisdictions alleging personal injuries associated with the use of the company’s vena cava filter products. In addition, three putative class actions have been filed against the company in various state courts on behalf of plaintiffs who are alleged to have no present injury (all lawsuits, collectively, the “Filter Product Claims”). The putative class actions, none of which has been certified, seek: (i) medical monitoring; (ii) punitive damages; (iii) a judicial finding of defect and causation; and/or (iv) attorneys’ fees. The first Filter Product Claim trial was completed in June 2012 and resulted in a judgment for the company based on the finding that the company was not liable for the plaintiff’s damages. The company expects additional trials of Filter Product Claims to take place over the next 12 months. While the company intends to vigorously defend the Filter Product Claims, it cannot give any assurances that the resolution of these claims will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In most product liability litigations of this nature, including the Hernia Product Claims, the Women’s Health Product Claims and the Filter Product Claims, plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions, and consequently, is unable to fully evaluate the claims. The company expects that it will receive and review additional information regarding the unsettled Hernia Product Claims, the Women’s Health Product Claims, the Filter Product Claims and related matters as these cases progress.

The company believes that many settlements and judgments, as well as legal defense costs, relating to product liability matters are or may be covered in whole or in part under its product liability insurance policies with a limited number of insurance carriers. In certain circumstances, insurance carriers reserve their rights with respect to coverage, or contest or deny coverage, as has occurred with respect to certain claims. When this occurs, the company intends to vigorously contest disputes with respect to its insurance coverage and to enforce its rights under the terms of its insurance policies, and accordingly, will record receivables with respect to amounts due under these policies, when recovery is probable. Amounts recovered under the company’s product liability insurance policies may be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.

The company’s insurance coverage with respect to the Hernia Product Claims has been depleted. In connection with the Hernia Product Claims, the company is in dispute with one of its excess insurance carriers relating to an aggregate of $25 million of insurance receivables.

In connection with the Women’s Health Product Claims, the company is in dispute with one of its excess insurance carriers relating to an aggregate of $50 million of insurance coverage.

Other Legal Matters

In November 2006, the company received a subpoena issued by the U.S. Department of Health and Human Services, Office of Inspector General (“OIG”), under the authority of the federal healthcare fraud and false claims statutes, seeking documents related to the company’s brachytherapy business (the “Brachytherapy Matter”). On January 27, 2012, the company announced that it had reached a preliminary agreement with the civil and criminal divisions of the United States Attorney’s Office for the Northern District of Georgia to resolve claims with respect to the Brachytherapy Matter. In connection with this preliminary agreement, the company recorded to other (income) expense, net, a charge of approximately $51.0 million ($40.8 million after tax) in the fourth quarter of 2011. The ultimate settlement of this matter is subject to the negotiation and execution of definitive agreements, which will likely include civil settlement and non-prosecution agreements, and a corporate integrity agreement with the OIG. If the definitive agreements are not finalized, the eventual costs related to this matter could be materially different than the previously recorded charge, and the company cannot give any assurances that this matter will not have a material adverse effect on the company’s business, results of operations, financial condition and/or liquidity.

In December 2007, a U.S. District Court jury in Arizona found that certain of W.L. Gore & Associates Inc.’s (“Gore”) ePTFE vascular grafts and stent-grafts infringe the company’s patent number 6,436,135. The jury upheld the validity of the patent and awarded the company $185 million in past damages. The jury also found that Gore willfully infringed the patent. In a second phase of the trial, the District Court ruled that Gore failed to prove that the patent is unenforceable due to inequitable conduct. In March 2009, the District Court doubled the jury award to approximately $371 million for damages through June 2007. The District Court also awarded the company attorneys’ fees of $19 million and prejudgment interest of approximately $20 million. In addition, the District Court denied Gore’s remaining motions, including its motions for a new trial and to set aside the jury’s verdict. In July 2010, the District Court awarded the company approximately $109 million in additional damages for the period from July 2007 through March 2009. Gore has deposited or secured the foregoing amounts with the District Court. The District Court also assessed a royalty rate of between 12.5% and 20%, depending on the product, that will be used to calculate damages for Gore’s infringing sales from April 2009 through the expiration of the patent. Gore has made additional deposits with the District Court of approximately $401 million, representing Gore’s calculation of royalties for its infringing sales through June 2012. Gore appealed this matter to the Court of Appeals for the Federal Circuit (the “Court of Appeals”), which on February 10, 2012 affirmed the decision of the District Court. Gore filed a petition with the Court of Appeals for a rehearing of its appeal. On June 14, 2012, the Court of Appeals reaffirmed its February 10, 2012 decision, including the ongoing royalty rates as set by the District Court, with the exception of the issue of willfulness with respect to Gore’s infringement of Bard’s patent number 6,436,135, which was remanded to the District Court. On October 12, 2012, Gore filed a petition for a writ of certiorari to the U.S. Supreme Court requesting a review of the portion of the decision that the Court of Appeals reaffirmed. Since the company considers this matter a gain contingency, no amounts have been recorded. Even if the company is ultimately successful in this lawsuit, it cannot give any assurances that royalties for Gore’s future infringing sales will remain at or near historic levels.

The company is subject to numerous federal, state, local and foreign environmental protection laws governing, among other things, the generation, storage, use and transportation of hazardous materials and emissions or discharges into the ground, air or water. The company is or may become a party to proceedings brought under various federal laws including the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), commonly known as Superfund, the Resource Conservation and Recovery Act, the Clean Water Act, the Clean Air Act and similar state or foreign laws. These proceedings seek to require the owners or operators of contaminated sites, transporters of hazardous materials to the sites and generators of hazardous materials disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. In most cases, there are other potentially responsible parties that may be liable for remediation costs. In these cases, the government alleges that the defendants are jointly and severally liable for the cleanup costs; however, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more closely reflects the relative contributions of the parties to the site contamination. The company’s potential liability varies greatly from site to site. For some sites, the potential liability is de minimis and for others the costs of cleanup have not yet been determined. Accruals for estimated losses from environmental remediation obligations generally are recognized no later than completion of the remedial feasibility study and are adjusted as further information develops or circumstances change. Costs of future expenditures for environmental remediation obligations are not discounted to their present value. Recoveries of environmental remediation costs from other parties are recorded as assets when their receipt is deemed probable. The company believes that the proceedings and claims described above will likely be resolved over an extended period of time. While it is not feasible to predict the outcome of these proceedings, based upon the company’s experience, current information and applicable law, the company does not expect these proceedings to have a material adverse effect on its financial condition and/or liquidity. However, one or more of the proceedings could be material to the company’s business and/or results of operations.

The company regularly monitors and evaluates the status of product liability and other legal matters, and may, from time-to-time, engage in settlement and mediation discussions taking into consideration developments in the matters and the risks and uncertainties surrounding litigation. These discussions could result in settlements of one or more of these claims at any time.

Accruals for product liability and other legal matters amounted to $168.8 million and $287.3 million at September 30, 2012 and December 31, 2011, respectively. Through September 30, 2012, the company made payments of $155.4 million to qualified settlement funds (“QSFs”), of which $6.2 million were made during the nine months ended September 30, 2012, subject to certain settlement conditions, for certain Hernia Product Claims. Payments to QSFs were recorded as a component of restricted cash. Total payments of $127.9 million from these QSFs have been made to qualified claimants, of which $125.8 million were made during the nine months ended September 30, 2012. In addition, other payments of $8.0 million have been made to qualified claimants, of which $5.4 million were made during the nine months ended September 30, 2012.

The company recorded receivables from insurance companies for product liability matters amounting to $55.7 million and $51.0 million at September 30, 2012 and December 31, 2011, respectively, of which $30.0 million, at September 30, 2012, is the subject of the disputes with certain excess insurance carriers, as noted above. After considering the nature of the claims, coverage provisions under the policies, relevant legal issues, the advice and judgment of outside legal counsel, and other pertinent factors, the company believes its claims are meritorious and that it will collect these receivables.

The company is unable to estimate the reasonably possible losses or range of losses, if any, arising from certain existing product liability matters and other legal matters. Under U.S. generally accepted accounting principles, an event is “reasonably possible” if “the chance of the future event or events occurring is more than remote but less than likely” and an event is “remote” if “the chance of the future event or events occurring is slight”. With respect to the Women’s Health Product Claims, the Filter Product Claims and the putative class action lawsuits that are part of the Hernia Product Claims, the company is unable to estimate a range of reasonably possible losses for the following reasons: (i) the proceedings are in early stages; (ii) the company has not received and reviewed complete information regarding the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, with respect to the putative class action lawsuits that are part of the Hernia Product Claims and the Filter Product Claims, there is uncertainty as to the likelihood of a class being certified or the ultimate size of the class.

XML

Pension and Other Postretirement Benefit Plans

9 Months Ended

Sep. 30, 2012

Pension and Other Postretirement Benefit Plans

10. Pension and Other Postretirement Benefit Plans

Defined Benefit Pension Plans - The company has both tax-qualified and nonqualified, noncontributory defined benefit pension plans, that together cover certain domestic and foreign employees. These plans provide benefits based upon a participant’s compensation and years of service.

The components of net periodic pension cost are as follows:

	Quarter Ended September  30,						Nine Months  Ended September 30,
	2012			2011			2012			2011
(dollars in millions)
Service cost, net of employee contributions	$	7.0		$	6.8		$	20.8		$	20.3
Interest cost		4.9			4.8			14.6			14.2
Expected return on plan assets		(6.2	)		(5.9	)		(17.9	)		(17.6	)
Amortization		2.8			1.9			7.8			5.9
Net periodic pension cost	$	8.5		$	7.6		$	25.3		$	22.8

Other Postretirement Benefit Plan - The company does not provide subsidized postretirement healthcare benefits and life insurance coverage except for a limited number of former employees. As this plan is unfunded, contributions are made as benefits are incurred. The net periodic benefit cost was $0.2 million for both quarters ended September 30, 2012 and 2011. The net periodic benefit cost was $0.5 million for both of the nine month periods ended September 30, 2012 and 2011.

XML

Location and Amounts of Gains and Losses on Derivative Instrument Designated as Fair Value Hedge (Detail) (Interest rate swap contract, Interest Expense, USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Interest rate swap contract | Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain Recognized on Swap	$ 1.0	$ 7.7	$ 2.5	$ 11.7
Loss Recognized on Long-Term Debt	$ (1.0)	$ (7.7)	$ (2.5)	$ (11.7)

XML

Inventories (Tables)

9 Months Ended

Sep. 30, 2012

Inventories

Inventories consisted of:

	September 30, 2012		December 31, 2011
(dollars in millions)
Finished goods	$	205.1	$	189.9
Work in process		20.1		21.3
Raw materials		110.7		108.0
	$	335.9	$	319.2

XML

Acquisition - Additional Information (Detail) (Subsequent Event, Neomend, Inc., USD $) In Millions, unless otherwise specified	Oct. 19, 2012
Subsequent Event | Neomend, Inc.
Business Acquisition [Line Items]
Business acquisition, purchase consideration cash payment	$ 140
Business acquisition, contingent consideration	$ 25.0
Business acquisition, contingent consideration payment due date	2016

XML

Segment Other Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Segment Reporting Information [Line Items]
Depreciation	$ 13.2	$ 12.2	$ 40.2	$ 39.0
Amortization	$ 20.4	$ 15.4	$ 61.2	$ 45.4

XML

Share-Based Compensation Plans - Additional Information (Detail) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended	9 Months Ended	1 Months Ended			1 Months Ended	3 Months Ended			1 Months Ended
	Mar. 31, 2012	Sep. 30, 2012 CompensationPlan	Apr. 18, 2012 Plan Of 2012	Sep. 30, 2012 Plan Of 2012	Sep. 30, 2012 Directors Plan	Apr. 18, 2012 Employee Stock Purchase Plan	Mar. 31, 2012 Performance Restricted Stock Units	Mar. 31, 2012 Performance Restricted Stock Units Minimum	Mar. 31, 2012 Performance Restricted Stock Units Maximum	Jul. 31, 2012 Management Stock Purchase Program	Jul. 31, 2011 Management Stock Purchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of remaining shares that may be issued				5,904,609	49,099
Additional shares authorized			2,750,000			750,000
Reduction in the number of total shares for each stock option or stock appreciation rights granted, per share			1
Reduction in the number of total shares for each award of other share based awards, per share			2.87
Number of employee stock purchase programs		2
Fair value assumptions, risk-free interest rate	0.41%									0.16%	0.12%
Fair value assumptions, dividend yield	0.85%									0.90%	0.80%
Fair value assumptions, expected life in years	2 years 9 months 29 days									7 months 6 days	7 months 6 days
Awards requisite service period, in years							3 years
Percentage of target payout of employee varying from actual payout under award								0.00%	200.00%
Number of shares granted in period										200,000	200,000
Fair value per share of shares granted in period										$ 38.33	$ 38.25
Fair value assumptions, expected volatility										20.00%	16.00%
Unrecognized compensation expenses related to share-based payment arrangements		$ 78.3
Weighted-average period of recognizing unrecognized compensation expenses related to share-based compensation, in years		2 years

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Accounts receivable, allowances	$ 11,700	$ 10,000
Preferred stock, par value	$ 1	$ 1
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued
Common stock, par value	$ 0.25	$ 0.25
Common stock, authorized	600,000,000	600,000,000
Common stock, issued	82,311,961	84,543,338
Common stock, outstanding	82,311,961	84,543,338

XML

Earnings per Common Share

9 Months Ended

Sep. 30, 2012

Earnings per Common Share

4. Earnings per Common Share

Earnings per share (“EPS”) is computed under the two-class method using the following common share information:

	Quarter Ended September  30,				Nine Months Ended September 30,
	2012		2011		2012		2011
(dollars and shares in millions)
EPS Numerator:
Net income	$	129.3	$	130.1	$	401.9	$	214.2
Less: Income allocated to participating securities		2.4		2.3		7.7		4.0
Net income available to common shareholders	$	126.9	$	127.8	$	394.2	$	210.2
EPS Denominator:
Weighted average common shares outstanding		83.4		86.6		83.8		86.0
Dilutive common share equivalents from share-based compensation plans		1.2		1.2		1.1		1.7
Weighted average common and common equivalent shares outstanding, assuming dilution		84.6		87.8		84.9		87.7

XML

Asset Impairments and Restructuring - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Jun. 30, 2012	Sep. 30, 2012
Restructuring Cost and Reserve [Line Items]
Asset impairment charges related to core technologies associated with biopsy business, pre tax	$ 13.2
Asset impairment charges related to core technologies associated with biopsy business, after tax	8.0
Asset impairment charges related to assets not related to operations, pre tax		9.0
Asset impairment charges related to assets not related to operations, after tax		5.8
Remaining liability related to restructuring charge	1.0		1.0
Cash payments related to restructuring charges			4.8
Reversal of restructuring costs			$ 1.6

XML

Accounts Receivable, Net of Allowances (Parenthetical) (Detail) (Subsequent Event, USD $) In Millions, unless otherwise specified	1 Months Ended
	Oct. 25, 2012
Subsequent Event
Accounts, Notes, Loans and Financing Receivable [Line Items]
Subsequent cash collection from account receivable	$ 0.6
Subsequent cash collection from account receivable greater than 365 days past due	$ 0.2

XML

Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2012

Location and Fair Value of Derivative Instruments Segregated Between Designated and Not Designated Hedging Instruments

The location and fair value of derivative instruments segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments recognized in the condensed consolidated balance sheets are as follows:

	Balance Sheet Location	Fair Value of Derivatives
Derivatives Designated as Hedging Instruments		September 30, 2012		December 31, 2011
(dollars in millions)
Forward currency contracts	Other current assets	$	1.3	$	1.5
Option currency contracts	Other current assets		2.7		4.3
Forward currency contracts	Other assets		0.3		—
Option currency contracts	Other assets		0.6		—
Interest rate swap contract	Other assets		14.6		12.1
		$	19.5	$	17.9
Forward currency contracts	Accrued expenses	$	0.8	$	6.4
Forward currency contracts	Other long-term liabilities		0.1		—
		$	0.9	$	6.4
Derivatives Not Designated as Hedging Instruments
(dollars in millions)
Forward currency contracts	Other current assets	$	—	$	3.8
		$	—	$	3.8

Location and Amounts of Gains and Losses on Derivative Instruments Designated as Cash Flow Hedges

The location and amounts of gains and losses on derivative instruments designated as cash flow hedges and the impact on shareholders’ investment are as follows:

	Gain/(Loss) Recognized  in Other Comprehensive Income						Location of Gain/(Loss) Reclassified from Accumulated Other Comp. Loss to Income	Gain/(Loss)  Reclassified from Accumulated Other Comp. Loss into Income
	Quarter Ended September 30,							Quarter Ended September  30,
	2012			2011				2012			2011
(dollars in millions)
Forward currency contracts	$	1.2		$	(4.3	)	Costs of goods sold	$	(0.3	)	$	(0.1	)
Option currency contracts		(1.1	)		0.2		Costs of goods sold		0.5			—
	$	0.1		$	(4.1	)		$	0.2		$	(0.1	)
	Gain/(Loss) Recognized in  Other Comprehensive Income						Location of Gain/(Loss) Reclassified from Accumulated Other Comp. Loss to Income	Gain/(Loss) Reclassified from Accumulated Other Comp. Loss into Income
	Nine Months Ended September 30,							Nine Months Ended September 30,
	2012			2011				2012			2011
(dollars in millions)
Forward currency contracts	$	3.3		$	(4.2	)	Costs of goods sold	$	(0.2	)	$	0.8
Option currency contracts		(1.2	)		0.1		Costs of goods sold		1.1			—
	$	2.1		$	(4.1	)		$	0.9	(A)	$	0.8	(A)

^(A)  The tax effect of the amount reclassified from accumulated other comprehensive loss to income was $0.2 million and $0.7 million at September 30, 2012 and 2011, respectively.

Location and Amounts of Gains and Losses on Derivative Instrument Designated as Fair Value Hedge

The location and amounts of gains and losses on the derivative instrument designated as a fair value hedge are as follows:

	Income  Statement Location	Gain Recognized on Swap								Loss Recognized on Long-Term Debt
		Quarter Ended September  30,				Nine Months  Ended September 30,				Quarter Ended September  30,						Nine Months  Ended September 30,
		2012		2011		2012		2011		2012			2011			2012			2011
(dollars in millions)
Interest rate swap contract	Interest expense	$	1.0	$	7.7	$	2.5	$	11.7	$	(1.0	)	$	(7.7	)	$	(2.5	)	$	(11.7	)

Location and Amounts of Gains and Losses on Derivative Instruments Not Designated as Hedging Instruments

The location and amounts of gains and losses on derivative instruments not designated as hedging instruments are as follows:

	Income  Statement Location	Gain/(Loss) Recognized in Earnings
		Quarter Ended September  30,					Nine Months  Ended September 30,
		2012		2011			2012		2011
(dollars in millions)
Forward currency contracts(A)	Other (income) expense, net	$	—	$	(5.1	)	$	3.0	$	(0.5	)

^(A) These derivative contracts mitigate changes in the value of remeasured foreign currency denominated intercompany loans attributable to changes in foreign currency exchange rates.

Financial Instrument Assets and (Liabilities) Measured at Fair Value on Recurring Basis

The following table summarizes certain financial instrument assets and (liabilities) measured at fair value on a recurring basis:

	September 30, 2012		December 31, 2011
(dollars in millions)
Foreign government bonds and notes	$	—	$	3.6
Forward currency contracts		0.7		(1.1	)
Option currency contracts		3.3		4.3
Interest rate swap contract		14.6		12.1

Accounts Receivable, Net of Allowances

At September 30, 2012, the company’s accounts receivable, net of allowances, from the national healthcare systems in these countries and amounts past due greater than 365 days are as follows:

	Accounts receivable, net		Greater than 365 days past due
(dollars in millions)
Spain	$	14.2	$	1.3
Italy		26.8		4.5
Greece		11.9		3.8
Portugal (A)		3.7		0.6
	$	56.6	$	10.2

^(A)  Subsequent cash collections in the fourth quarter of 2012 were approximately $0.6 million, of which $0.2 million related to receivables greater than 365 days past due.